Accolade (ACCD) 10-Q 1 Jul 22 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	May 31, 2022	Jun. 22, 2022
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	May 31, 2022
Entity File Number	001-39348
Entity Registrant Name	ACCOLADE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	01-0969591
Entity Address State Or Province	WA
Entity Address, Address Line One	1201 Third Avenue
Entity Address, Address Line Two	Suite 1700
Entity Address, City or Town	Seattle
Entity Address, Postal Zip Code	98101
City Area Code	206
Local Phone Number	926-8100
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ACCD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		71,209,436
Entity Central Index Key	0001481646
Current Fiscal Year End Date	--02-28
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	May 31, 2022	Feb. 28, 2022
Current assets:
Cash and cash equivalents	$ 335,628	$ 365,853
Accounts receivable, net	21,739	21,116
Unbilled revenue	6,739	9,685
Current portion of deferred contract acquisition costs	3,179	3,015
Prepaid and other current assets	10,282	9,468
Total current assets	377,567	409,137
Property and equipment, net	11,865	11,797
Operating lease right-of-use assets	33,790	33,126
Goodwill	278,191	577,896
Intangible assets, net	234,318	244,690
Deferred contract acquisition costs	7,148	7,205
Other assets	1,575	1,678
Total assets	944,454	1,285,529
Current liabilities:
Accounts payable	7,777	7,837
Accrued expenses and other current liabilities	9,745	11,000
Accrued compensation	22,954	39,189
Due to customers	11,104	16,263
Current portion of deferred revenue	36,883	30,875
Current portion of operating lease liabilities	7,016	6,589
Total current liabilities	95,479	111,753
Loans payable, net of unamortized issuance costs	281,083	280,666
Operating lease liabilities	32,542	32,486
Other noncurrent liabilities	563	4,562
Deferred revenue	280	268
Total liabilities	409,947	429,735
Commitments and Contingencies (note 12)
Stockholders' equity
Common stock par value $0.0001; 500,000,000 shares authorized; 69,610,341 and 67,098,477 shares issued and outstanding at May 31, 2022 and February 28, 2022, respectively	7	7
Additional paid-in capital	1,371,966	1,350,431
Accumulated deficit	(837,466)	(494,644)
Total stockholders' equity	534,507	855,794
Total liabilities and stockholders' equity	$ 944,454	$ 1,285,529

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	May 31, 2022	Feb. 28, 2022
Consolidated Balance Sheets
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	69,610,341	67,098,477
Common stock, shares outstanding	69,610,341	67,098,477

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Consolidated Statements of Operations
Revenue	$ 85,528	$ 59,527
Cost of revenue, excluding depreciation and amortization	47,615	35,936
Operating expenses:
Product and technology	26,817	15,939
Sales and marketing	25,614	14,509
General and administrative	20,238	22,002
Depreciation and amortization	11,576	8,696
Goodwill impairment	299,705
Change in fair value of contingent consideration		10,460
Total operating expenses	383,950	71,606
Loss from operations	(346,037)	(48,015)
Interest expense, net	(634)	(618)
Other expense	(50)	(55)
Loss before income taxes	(346,721)	(48,688)
Income tax expense	3,899	(19)
Net loss	$ (342,822)	$ (48,707)
Net income (loss) per share, Basic	$ (4.92)	$ (0.84)
Net income (loss) per share, Diluted	$ (4.92)	$ (0.84)
Weighted-average common shares outstanding, Basic	69,738,638	58,261,233
Weighted-average common shares outstanding, Diluted	69,738,638	58,261,233

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) - USD ($) $ in Thousands	Common stock	Additional paid-in capital	Accumulated deficit	Total
Balance at Feb. 28, 2021	$ 6	$ 762,362	$ (371,520)	$ 390,848
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with acquisition		116,187		116,187
Issuance of common stock in connection with acquisition (shares)	2,822,242
Issuance of replacement awards in connection with acquisition		1,520		1,520
Exercise of stock options and vesting of restricted stock units		2,141		2,141
Exercise of stock options and vesting of restricted stock units (shares)	236,982
Purchase of capped calls		(34,503)		(34,503)
Issuance of common stock in connection with the employee stock purchase plan		1,948		1,948
Issuance of common stock in connection with the employee stock purchase plan (shares)	50,516
Stock-based compensation expense		7,675		7,675
Net loss			(48,707)	(48,707)
Balance at May. 31, 2021	$ 6	857,330	(420,227)	437,109
Balance (shares) at May. 31, 2021	58,808,792
Balance (shares) at Feb. 28, 2021	55,699,052
Balance at Feb. 28, 2022	$ 7	1,350,431	(494,644)	855,794
Balance (shares) at Feb. 28, 2022	67,098,477
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with acquisition (shares)	1,939,853
Exercise of stock options and vesting of restricted stock units		358		358
Exercise of stock options and vesting of restricted stock units (shares)	228,701
Issuance of common stock in connection with the employee stock purchase plan		1,788		1,788
Issuance of common stock in connection with the employee stock purchase plan (shares)	343,310
Stock-based compensation expense		19,389		19,389
Net loss			(342,822)	(342,822)
Balance at May. 31, 2022	$ 7	$ 1,371,966	$ (837,466)	$ 534,507
Balance (shares) at May. 31, 2022	69,610,341

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Cash flows from operating activities:
Net loss	$ (342,822)	$ (48,707)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill impairment	299,705
Depreciation and amortization expense	11,576	8,696
Amortization of deferred contract acquisition costs	817	602
Change in fair value of contingent consideration		10,460
Deferred income taxes	(3,999)
Noncash interest expense	419	379
Stock-based compensation expense	19,389	7,675
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable and unbilled revenue	2,323	(409)
Accounts payable and accrued expenses	(1,258)	268
Deferred contract acquisition costs	(924)	(507)
Deferred revenue and due to customers	862	7,643
Accrued compensation	(15,598)	(13,247)
Other liabilities	(240)	(82)
Other assets	(711)	(385)
Net cash used in operating activities	(30,461)	(27,614)
Cash flows from investing activities:
Purchase of marketable securities		(99,998)
Capitalized software development costs	(766)
Purchases of property and equipment	(506)	(701)
Cash paid for acquisition, net of cash acquired		(228,013)
Net cash used in investing activities	(1,272)	(328,712)
Cash flows from financing activities:
Proceeds from stock option exercises	358	1,991
Payments of equity issuance costs		(23)
Payment of debt issuance costs		(8,101)
Payment for purchase of capped calls		(34,443)
Proceeds from employee stock purchase plan	1,150	1,026
Proceeds from borrowings on debt		287,500
Net cash provided by financing activities	1,508	247,950
Net decrease in cash and cash equivalents	(30,225)	(108,376)
Cash and cash equivalents, beginning of period	365,853	433,884
Cash and cash equivalents, end of period	335,628	325,508
Supplemental cash flow information:
Interest paid	769	51
Fixed assets included in accounts payable	228	292
Other receivable related to stock option exercises	5	247
Income taxes paid	$ 22	31
Common stock issued in connection with acquisition		116,187
Replacement awards issued in connection with acquisition		1,520
Debt issuance and offering costs included in accounts payable and accrued expenses		$ 304

Background

Background	3 Months Ended
	May 31, 2022
Background
Background	(1) Background Accolade, Inc. (Accolade or together with its subsidiaries, the Company) provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. The Company’s customers are primarily employers that contract with Accolade to provide their employees and their employees’ families (the members) a single place to turn for their health, healthcare, and benefits needs. The Company also offers expert medical opinion services to employer customers and virtual primary care and mental health support, both directly to consumers and to employer customers. These services are designed to drive better healthcare outcomes and increased satisfaction for the participants while lowering costs for the payor. The Company provides its services to customers throughout the United States. Accolade is co-headquartered in Seattle, Washington and Plymouth Meeting, Pennsylvania.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	May 31, 2022
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies	(2) Basis of Presentation and Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended February 28, 2022 appearing in the Company’s Annual Report on Form 10-K and filed with the Securities and Exchange Commission (the SEC) on May 2, 2022. (a) Basis of Presentation and Principles of Consolidation Accolade’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and include the Company’s accounts and those of the Company’s wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Through the acquisition of PlushCare, Inc. (PlushCare), the Company has various administrative service agreements (ASA) with professional medical corporations established in California, Illinois, Wyoming, and New Jersey (PC). The PCs employ or contract with medical providers who provide services via the Company’s technology platform. The ASAs are evergreen and are terminable by the parties for breach or bankruptcy. Through the ASAs, the Company provides non-clinical administrative services to the PCs and manages the economic activities that most significantly affect PCs. The PCs retain control over the provision of medical services and the PC’s clinical personnel. The PCs are variable interest entities (VIE) to the Company. Under Accounting Standards Codification Subtopic 810 – Consolidation The PCs and the Company are independent entities, and as such creditors of the PCs do not have recourse against the Company in the event of default by the PCs. Additionally, the PCs’ non-cash assets are available to the Company to satisfy obligations or for other corporate purposes. (b) Unaudited Interim Financial Statements The accompanying consolidated financial statements and the related footnote disclosures are unaudited. The unaudited consolidated interim financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s interim consolidated financial position as of May 31, 2022, the results of its operations for the three months ended May 31, 2022 and 2021, and its cash flows for the three months ended May 31, 2022 and 2021. The results for the three months ended May 31, 2022 are not necessarily indicative of results to be expected for the year ending February 28, 2023, any other interim periods, or any future year or period. The Company’s management believes that the disclosures are adequate to make the information presented not misleading when read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended February 28, 2022. (c) Capitalized Internal-Use Software Costs Costs related to software acquired, developed, or modified solely to meet the Company’s internal requirements, including tools that enable the Company’s employees to interact with members and their providers, with no substantive plans to market such software at the time of development, are capitalized. Costs incurred during the preliminary planning and evaluation stage of the project and during the post-implementation operational stage are expensed as incurred. Costs related to minor upgrades, minor enhancements, and maintenance activities are expensed as incurred. Costs incurred during the application development stage of the project are capitalized. Internal-use software is included in property and equipment and is amortized on a straight-line basis over 3 years. For the three months ended May 31, 2022 and 2021, the Company capitalized $766 and $0, respectively, for internal-use software. Amortization expense related to capitalized internal-use software during the three months ended May 31, 2022 and 2021 was $290 and $1,214, respectively. (d) Impairment of Long-Lived Assets The Company reviews long-lived assets, such as property and equipment and finite-lived intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset. There were no long-lived asset impairment charges recorded during the three months ended May 31, 2022 and 2021. (e) Intangible Assets The Company has acquired intangible assets in the form of developed technology, customer relationships, trade names, supplier-based network, and non-compete agreements through various acquisitions. Intangible assets are recorded at fair value on the date of acquisition and are subject to amortization over the estimated useful lives of each asset. Estimates of fair value and useful lives are based on historical factors, current circumstances, and the experience and judgment of management. Estimates and assumptions used to value intangible assets are evaluated by management on an ongoing basis. (f) Goodwill Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit. The Company performs its annual goodwill impairment test on an annual basis in the fourth quarter of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded. A goodwill impairment loss was recorded during the three months ended May 31, 2022. See Note 5 for further information. ( g ) Revenue and Deferred Revenue Revenue Recognition The Company generates revenue by providing customers access to its advocacy, expert medical opinion, and virtual primary care and mental health support services, as well as through utilization of its expert medical opinion and virtual primary care and mental health support services that were acquired through the acquisitions of Innovation Specialists LLC d/b/a 2nd.MD (2nd.MD) and PlushCare. Contracts with customers that include expert medical opinion or virtual primary care and mental health support services may contain either an access fee, a utilization-based fee, or both. In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers ● identification of the contract, or contracts with a customer; ● identification of the performance obligations in the contract; ● determination of the transaction price; ● allocation of the transaction price to the performance obligations in the contracts; and ● recognition of revenue when, or as, the Company satisfies a performance obligation. At contract inception, the Company assesses the type of services being provided and assesses the performance obligations in the contract. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on overall pricing objectives, taking into consideration market conditions and other factors, using an expected cost plus margin approach. The Company considered the variable consideration allocation exception in ASC 606 for its advocacy contracts and concluded that such exception for allocating variable consideration to distinct performance obligations or distinct time periods within a series was not met primarily due to variability in its per-member-per-month (PMPM) pricing. The majority of fees earned by the Company are considered to be variable consideration due to both the uncertainty regarding the total number of members, consultations or visits for which the Company will invoice the customer, as well as the variable PMPM fees that are dependent upon the achievement of performance metrics and/or healthcare cost savings. Performance metrics are measured monthly, quarterly, or annually, and with respect to the achievement of healthcare cost savings targets, annually (typically measured on a calendar year basis). Accordingly, at contract inception and on an ongoing basis, as part of the Company’s estimate of the transaction price, the Company determines whether any such fees should be constrained, and the Company includes the estimated consideration for those fees to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur (and is therefore considered to be unconstrained). Consideration related to the Company’s achievement of healthcare cost savings is typically constrained until the end of the applicable calendar year due to uncertainty related to factors outside of the Company’s control. Consideration related to other performance metrics is typically not constrained based on the Company’s prior success of achieving such metrics. On an ongoing basis, the Company reassesses its estimates for variable consideration, which can change based upon its assessment of the achievement of performance metrics and healthcare cost savings, as well as the number of members, consultations, or visits. Access Fees The Company generates revenue primarily from contracts with customers to access the Company’s advocacy, expert medical opinion, and virtual primary care and mental health support services. The Company prices access fees primarily using a recurring PMPM fee, typically with a portion of the fee calculated as the product of a fixed rate times the number of members (fixed PMPM fee), plus a variable PMPM fee calculated as the product of a variable rate times the number of members (variable PMPM fee). The fees associated with the variable PMPM fee can be earned through the achievement of performance metrics and/or the realization of healthcare cost savings resulting from use of the Company’s services. Collectively, the fixed PMPM fee and variable PMPM fee are referred to as the total PMPM fee. The Company’s PMPM pricing varies by contract. In certain contracts, the maximum total PMPM fee varies during the contract term (total PMPM rate increases or decreases annually), while in other contracts, the total PMPM maximum fee is consistent over the term, yet the fixed and variable portions vary. For example, in certain contracts the fixed PMPM fee increases on an annual basis while the variable PMPM fee decreases on an annual basis, resulting in the same total PMPM fee throughout the term of the contract. The PMPM fees for expert medical opinion and virtual primary care and mental health support services may be tiered based upon the customer’s utilization. Access to the Company’s services represent a single stand-ready performance obligation. The Company’s contracts include stand-ready services to provide eligible participants with access to the Company’s services and to perform an unspecified quantity of interactions with members during the contract period. Accordingly, the Company’s services are generally viewed as stand-ready performance obligations comprised of a series of distinct daily services that are substantially the same and have the same pattern of transfer. For advocacy services, the Company satisfies these performance obligations over time and recognizes revenue related to its services as the services are provided using a measure of progress based upon the actual number of members eligible for the service during the respective period as a percentage of the estimated members expected to be eligible for the service over the term of the contract. The Company believes a measure of progress based on the number of members is the most appropriate measurement of control of the services being transferred to the customer as the amount of internal resources necessary to stand-ready is directly correlated to the number of members who can use the services. For the majority of expert medical opinion services, the Company satisfies these performance obligations over time and recognizes revenue in the amount of consideration for which it has the right to invoice using the as-invoiced practical expedient. Access fees also include access to the Company’s virtual primary care and mental health support services sold directly to consumers on a monthly or yearly fixed fee subscription basis. For these services, the Company satisfies these stand-ready performance obligations over time and recognizes revenue ratably over the subscription period. Utilization-based fees The Company also generates revenue when members utilize the expert medical opinion and virtual primary care and mental health support services that are billed based on utilization. Many, but not all, contracts with customers contain utilization-based fees. For any utilization-based fees, the Company satisfies these performance obligations over time and recognizes revenue in the amount of consideration for which it has the right to invoice using the as-invoiced practical expedient for any consultations or visits sold to enterprise customers as well as any non-insured consultations or visits related to virtual primary care and mental health support services sold directly to consumers. For any consultations or visits that are paid through insurance claims, the Company recognizes revenue as the consultations and visits occur in an amount that reflects the consideration that is expected based upon then-current prices and historical experience from insurance payors. Deferred Revenue The Company typically invoices its customers in advance of the services performed on a monthly or quarterly basis, and the amount invoiced typically represents the maximum total PMPM fee for the estimated number of eligible members over the applicable invoice period. The total PMPM fee covers the stand-ready services in the Company’s typical contracts (i.e., the performance obligations are not separately priced or invoiced). The maximum total PMPM fee that is invoiced includes both the fixed PMPM fee and the variable PMPM fee related to the performance metrics and/or the realization of healthcare cost savings that can be achieved during the period. These fees are classified as deferred revenue on the Company’s consolidated balance sheet until such time that revenue can be recognized. In the event the Company fails to satisfy any of the performance metrics and/or realization of healthcare cost savings that are billed in advance, the Company will refund the applicable portion of the fee or offset the amount against a future invoice. These amounts are included in due to customers on the Company’s consolidated balance sheet. The Company’s accounts receivable represent rights to consideration that are unconditional. ( h ) Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and marketable securities. The Company maintains its cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. The Company invests its cash equivalents in highly rated money market funds. Marketable securities are comprised of United States treasury bills with original maturities greater than 90 days. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions. Significant customers are those which represent 10% or more of the Company’s revenue during the periods. For each significant customer, revenue as a percentage of total revenue was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended May 31, ​ ​ 2022 2021 ​ Customer 1 * % 11.9 % ​ *For the three months ended May 31, 2022, no customer represented 10% or more of the Company’s revenue. ( i ) Marketable Securities The Company classifies its marketable securities as available-for-sale, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair market value. ​ (j) Leases In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases The Company adopted Topic 842 on February 28, 2022, with an effective date of adoption of March 1, 2021, using the modified retrospective approach. Topic 842 requires the Company to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on its consolidated balance sheet for most leases and disclose key information about leasing arrangements. The Company elected to utilize the package of practical expedients available under Topic 842, which allowed it to not reassess: (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases, and (iii) the initial direct costs for existing leases. As a result of the adoption, the Company recorded operating lease right-of-use assets and operating lease liabilities of $34,739 and $38,740, respectively, on the consolidated balance sheet as of March 1, 2021. Whenever the Company enters into a new arrangement, it determines, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the right to direct the use of, and obtain substantially all the economic benefits from, the use of the underlying asset. If a lease exists, the Company then determines the separate lease and non-lease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect, and is not significantly affected by, other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered non-lease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and non-lease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and non-lease components. For each lease, the Company then determines the lease term, the present value of lease payments, and the classification of the lease as either an operating or finance lease. The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor. ​ The present value of lease payments is calculated based on: ​ (1) Lease payments – Lease payments included in the measurement of the lease asset or liability comprise the following: fixed payments (including in-substance fixed payments), and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise. ​ (2) Discount rate – the discount rate is determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term. In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee’s and lessor’s rights, obligations, and economic incentives over the term of the lease. The Company does not recognize leases with an initial term of 12 months or less on its consolidated balance sheets and will recognize these payments in the consolidated statements of operations on a straight-line basis over the lease term. Certain leases contain variable payments which are based on usage or operating costs, such as utilities and maintenance. These payments are not included in the measurement of the lease liability or corresponding right-of-use asset due to the uncertainty of the payment amount and are recorded as lease expense in the period incurred. Prior to the adoption of Topic 842, the Company accounted for leases under FASB ASC Topic 840, Leases

Revenue

Revenue	3 Months Ended
	May 31, 2022
Revenue
Revenue	(3) Revenue The following table presents the Company’s revenues disaggregated by revenue source: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended May 31, ​ 2022 2021 Access fees $ 68,125 ​ $ 56,205 Utilization-based fees 17,403 ​ 3,322 Total $ 85,528 ​ $ 59,527 ​ As of May 31, 2022, $243,744 of revenue is expected to be recognized from remaining performance obligations and is expected to be recognized as follows: ​ ​ ​ ​ Fiscal year ending February 28(29), ​ ​ Remainder of 2023 $ 127,326 2024 73,836 2025 39,813 2026 2,769 Total $ 243,744 ​ The expected revenue includes variable fee estimates for the non-cancellable term of the Company’s contracts. The expected revenue does not include amounts of variable consideration that are constrained. Significant changes to the contract liability balances during the three months ended May 31, 2022 and 2021 were the result of revenue recognized as well as net cash received and liabilities assumed associated with the acquisitions of 2nd.MD and PlushCare (during the three months ended May 31, 2021). Significant changes in the deferred revenue balances during the three months ended May 31, 2022 and 2021 were the result of recognized revenue of $24,447 and $18,925, respectively, that were previously included in deferred revenue. In addition, significant changes to the contract asset balances during the three months ended May 31, 2022 and 2021 were the result of revenue recognized as well as transfers to accounts receivable. Contract assets relating to unbilled revenue are transferred to accounts receivable when the right to consideration becomes unconditional. Revenue related to performance obligations satisfied in prior periods that was recognized during the three months ended May 31, 2022 and 2021 was $1,829 and $1,410, respectively. These amounts relate to the ratable recognition through the minimum contract term of performance obligations satisfied in prior periods related to the Company’s achievement of healthcare cost savings. Cost to obtain and fulfill a contract The Company capitalizes sales commissions paid to internal sales personnel that are both incremental to the acquisition of customer contracts and recoverable. These costs are recorded as deferred contract acquisition costs in the accompanying consolidated balance sheets. The Company capitalized commission costs of $838 and $427 for the three months ended May 31, 2022 and 2021, respectively. The Company defers costs based on its sales compensation plans only if the commissions are incremental and would not have occurred absent the customer contract. Payments to direct sales personnel are typically made upon signature of the contract. The Company does not pay commissions on contract renewals. Deferred commissions are paid over the first year of a contract and are amortized ratably over an estimated period of benefit of five years, which is the estimated customer life. The Company determined the period of amortization for deferred commissions by taking into consideration current customer contract terms, historical customer retention, and other factors. Amortization is included in sales and marketing expenses in the accompanying consolidated statements of operations and totaled $592 and $438 for the three months ended May 31, 2022 and 2021, respectively. The Company periodically reviews deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the estimated period of benefit. There were no impairment losses recorded during the periods presented. For certain customer contracts, the Company may incur direct and incremental costs related to customer set-up and implementation. The Company recorded deferred implementation costs of $86 and $81 for the three months ended May 31, 2022 and 2021, respectively. These implementation costs are deferred and amortized over the expected useful life of the Company’s customers, which is five years. Amortization is included in cost of revenues in the Company’s consolidated statements of operations and totaled $225 and $164 for the three months ended May 31, 2022 and 2021, respectively.

Acquisitions

Acquisitions	3 Months Ended
	May 31, 2022
Acquisitions
Acquisitions	(4) Acquisitions Acquisition of 2nd.MD ​ On March 3, 2021, the ​ The consideration paid was comprised of cash, common stock, and contingent consideration as follows: ​ ​ ​ ​ ​ Consideration ​ Cash consideration, net of cash acquired ​ $ 226,135 Fair value of common stock issued ​ 116,187 Fair value of replacement awards ​ ​ 1,520 Fair value of contingent consideration ​ 76,248 Total consideration ​ $ 420,090 ​ The aggregate purchase consideration of $420,090 was provided through cash of $226,135 (net of $205 cash acquired) and the issuance of up to 4,384,882 shares of the Company’s common stock, of which 2,822,242 were issued upon closing of the acquisition, of which 2,495,441 were fully vested at the time of issuance with the remaining 326,801 vesting over future service periods. The cash consideration in the above table includes the repayment of of $13,026 . The contingent consideration represented potential obligations for the Company to issue up to 2,170,972 additional shares of its common stock to the selling shareholders of is comprised of two earnout scenarios associated with (1) a contract renewal and (2) the achievement of certain future revenue milestones. As a result of the contract renewal and achievement of certain revenue milestones, the Company will issue a total of 1,977,343 shares of its common stock, of which 1,939,853 shares of common stock were issued in May 2022. The estimated fair value of the replacement awards issued in the above table is comprised of 120,760 restricted stock units issued to 2nd.MD employees with an estimated fair value of $5,434 of which $1,520 was attributable to pre-acquisition services. The remaining estimated value of $3,914 associated with the replacement awards is attributable to post-acquisition services and will be expensed over the future requisite service periods of the awards. Several key 2nd.MD employees entered into agreements with the Company whereby their pro rata portion of shares issued at closing and upon achievement of the contingent consideration milestones are also subject to continuous employment with the Company and vest annually over a period of two years following the acquisition date. Upon voluntary termination of employment, any unvested shares will be forfeited. Due to the risk of forfeiture upon termination of employment, the aggregate 326,801 shares issued at closing and the aggregate shares eligible to be issued upon achievement of the contingent consideration milestones of 281,531 shares were excluded from the purchase price and contingent consideration. These shares are accounted for as stock-based compensation expense in the post business combination periods. The estimated fair value of the contingent consideration associated with future revenue milestones was determined using a Monte Carlo simulation. The Monte Carlo simulation performs numerous simulations utilizing certain assumptions such as (i) projected eligible revenues, (ii) expected term, (iii) risk-free rate, (iv) risk-adjusted discount rate, (v) share volatility and (vi) operational leverage ratio between revenues and earnings before interest, taxes, depreciation and amortization (EBITDA). The Company accounted for the acquisition of 2nd.MD under the U.S. GAAP business combinations guidance. This accounting requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The allocation of the purchase price to the assets acquired and liabilities assumed was subject to further adjustment within the measurement period (up to one year from the acquisition date). Measurement period adjustments since initial preliminary estimates reported in the first quarter of fiscal 2022 were primarily related to an updated working capital calculation. The cumulative effect of all measurement period adjustments resulted in a decrease to recognized goodwill of $1,878 . As of February 28, 2022, the purchase price allocation was considered complete. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition. ​ ​ ​ ​ ​ Assets acquired: ​ Accounts receivable ​ $ 5,550 Unbilled revenue ​ ​ 226 Current portion of deferred contract acquisition costs ​ ​ 176 Prepaid and other current assets ​ 1,052 Property and equipment ​ ​ 4,344 Deferred contract acquisition costs ​ ​ 564 Goodwill ​ 208,286 Intangible assets (1) ​ ​ Customer relationships ​ ​ 120,000 Technology ​ ​ 58,000 Supplier-based network ​ ​ 25,000 Trade name ​ ​ 3,400 Non-compete agreement ​ ​ 3,100 Total assets acquired ​ $ 429,698 ​ ​ Liabilities assumed: ​ Accounts payable ​ $ 1,195 Accrued expenses ​ ​ 585 Accrued compensation ​ ​ 3,817 Deferred rent and other current liabilities ​ 904 Due to customers ​ ​ 294 Current portion of deferred revenue ​ ​ 625 Deferred rent and other noncurrent liabilities ​ ​ 2,188 Total liabilities assumed ​ $ 9,608 ​ ​ Net assets acquired ​ $ 420,090 (1) The weighted-average useful life of intangible assets acquired is approximately 14 years . ​ The purchase price was allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The identifiable intangible assets included and are being amortized on a straight-line basis ranging from 3 years to 20 years . The technology intangible asset was valued using the estimated replacement cost method. This method requires several judgments and assumptions to determine the fair value, including expected profits and opportunity cost. Goodwill is attributable to the workforce of 2nd.MD as well as expected future growth into new and existing markets and is deductible for income tax purposes. Acquisition of PlushCare ​ On June 9, 2021, the ​ The consideration paid was comprised of cash, common stock, and contingent consideration as follows: ​ ​ ​ ​ ​ Consideration ​ Fair value of common stock issued ​ $ 330,338 Fair value of contingent consideration ​ 44,618 Cash consideration, net of cash acquired ​ ​ 33,860 Fair value of replacement awards ​ ​ 5,209 Total consideration ​ $ 414,025 ​ The aggregate purchase consideration of $414,025 was provided through cash of $33,860 (net of $17,837 cash acquired and $1,463 of debt repaid) and the issuance of 7,144,393 shares of the Company’s common stock, of which 854,717 are subject to future vesting and excluded from consideration paid. The contingent consideration represented a potential obligation for the Company to issue up to an additional 1,429,556 shares of its common stock and up to approximately $2,000 in cash upon the achievement of defined revenue milestones following the closing. Up to 102,111 shares of this contingent consideration will be withheld from being issued to the selling shareholders of PlushCare until the resolution of a pending litigation matter. The contingency was resolved at December 31, 2021, and as a result the Company issued 1,327,445 shares of its common stock subsequent to May 31, 2022, excluding the 102,111 shares that are withheld pending the resolution of the litigation matter. The estimated fair value of the replacement awards issued in the above table is comprised of 325,992 options to purchase Accolade common stock issued to PlushCare employees as of the acquisition date with an estimated fair value of $16,663 , of which $5,209 was attributable to pre-acquisition services. The remaining estimated value of $11,454 associated with the replacement awards is attributable to post-acquisition services and will be expensed over the future requisite service periods of the awards. Certain key PlushCare employees entered into agreements with the Company whereby a portion of their shares issued at closing are subject to continuous employment with the Company and vest annually over a three-year period following the acquisition date. Upon voluntary termination of employment, any unvested shares will be forfeited. Due to the risk of forfeiture upon termination of employment, the 806,161 shares subject to forfeiture have been excluded from the purchase price and are accounted for as stock-based compensation expense in the post-business combination periods. Also, one PlushCare employee received 48,556 shares of unvested common stock. These shares vest on a pro rata basis monthly through May 2023. The estimated fair value of the contingent consideration associated with future revenue milestones was determined using a Monte Carlo simulation. The Monte Carlo simulation performs numerous simulations utilizing certain assumptions such as (i) projected eligible revenues, (ii) expected term, (iii) risk-free rate, (iv) risk-adjusted discount rate, (v) share volatility, and (vi) operational leverage ratio between revenues and earnings before interest, taxes, depreciation, and amortization (EBITDA). reclassified the value of the contingent consideration from a liability into stockholders’ equity in the consolidated balance sheet. The Company accounted for the acquisition of PlushCare under the U.S. GAAP business combinations guidance. This accounting requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The allocation of the purchase price to the assets acquired and liabilities assumed was subject to further adjustment within the measurement period (up to one year from the acquisition date). Measurement period adjustments since initial preliminary estimates reported in the second quarter of fiscal 2022 were primarily related to updated assessments of acquired deferred tax liability and accounts receivable. The cumulative effect of all measurement period adjustments resulted in a decrease to recognized goodwill of $1,685 . As of May 31, 2022, the purchase price allocation was considered complete. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition. ​ ​ ​ ​ ​ Assets acquired: ​ Accounts receivable ​ $ 1,359 Prepaid and other current assets ​ 573 Property and equipment ​ ​ 298 Other noncurrent assets ​ ​ 932 Goodwill ​ 365,597 Intangible assets (1) ​ ​ Customer relationships ​ ​ 4,050 Technology ​ ​ 40,650 Trade name ​ ​ 10,300 Non-compete agreements ​ ​ 6,200 Total assets acquired ​ $ 429,959 ​ ​ Liabilities assumed: ​ Accounts payable ​ $ 1,532 Accrued expenses ​ ​ 193 Accrued compensation ​ ​ 2,117 Current portion of deferred revenue ​ ​ 1,212 Deferred tax liability ​ ​ 9,992 Other liabilities ​ ​ 888 Total liabilities assumed ​ $ 15,934 ​ ​ Net assets acquired ​ $ 414,025 (1) The weighted-average useful life of intangible assets acquired is approximately 5 years . ​ The purchase price was allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The identifiable intangible assets included and are being amortized on a straight-line basis ranging from 2 years to 10 years . The technology intangible asset was valued using the estimated replacement cost method. This method requires several judgments and assumptions to determine the fair value, including expected profits and opportunity cost. Goodwill is attributable to the workforce of PlushCare as well as expected future growth into new and existing markets and is not deductible for income tax purposes. Unaudited Pro Forma Financial Information The following table reflects the pro forma operating results for the Company which gives effect to the acquisitions of 2nd.MD and PlushCare as if they had occurred on March 1, 2020. The pro forma results are based on assumptions that the Company believes are reasonable under the circumstances. The pro forma results are not necessarily indicative of future results. The pro forma financial information includes the historical results of the Company, 2nd.MD, and PlushCare adjusted for certain items, which are described below, and does not include the effects of any synergies or cost reduction initiatives related to the acquisitions of 2nd.MD or PlushCare. ​ ​ ​ ​ ​ ​ ​ Unaudited Pro Forma ​ ​ Three months ended May 31, 2021 Revenue ​ $ 72,532 Net loss ​ $ (63,099) ​ Pro forma net income (loss) for the three months ended May 31, 2021 reflect adjustments primarily related to interest expense, the amortization of intangible assets and stock-based compensation expense. The unaudited pro forma financial information is not necessarily indicative of what the Company’s consolidated results actually would have been if the acquisition had been completed at the beginning of the respective periods. Acquisition of HealthReveal On September 30, 2021, the Company acquired substantially all the assets of HealthReveal, Inc. (HealthReveal). HealthReveal is a clinical artificial intelligence company focused on ensuring patients receive optimal, personalized chronic care to preempt adverse outcomes. Under the terms of the agreement, the Company issued 252,808 shares of common stock as consideration at closing. The Company will issue up to 28,089 additional shares of common stock that are subject to an indemnity holdback, and these shares will be released 18 months following the closing. The Company accounted for this transaction as an asset acquisition based on an evaluation of the U.S. GAAP guidance for business combinations. The Company concluded that the developed technology acquired from HealthReveal comprised substantially all of the fair value of the gross assets acquired and that the assets acquired did not meet the definition of a business under the guidance for business combinations. The developed technology intangible asset was recorded at $9,976 on the acquisition date and is being amortized on a straight-line basis over 3 years . Acquisition and Integration-Related Costs ​ Acquisition and integration-related costs include banking, legal, accounting, and consulting fees. he Company incurred cquisition and integration-related costs that were expensed immediately and recorded in general and administrative expenses in the Company’s consolidated statements of operations.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	May 31, 2022
Goodwill and Intangible Assets
Goodwill and Intangible Assets	(5) Goodwill and Intangible Assets The following table presents changes in the carrying amount of goodwill for the three months ended May 31, 2022: ​ ​ ​ ​ ​ Balance, February 28, 2022 ​ $ 577,896 Impairment ​ ​ (299,705) Balance, May 31, 2022 ​ $ 278,191 ​ Annually, and upon the identification of a triggering event, management is required to perform an evaluation of the recoverability of goodwill. Triggering events potentially warranting an interim goodwill impairment test include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained declines in the Company’s stock price or market capitalization, considered both in absolute terms and relative to peers. ​ As a result of sustained decreases in the Company’s stock price and market capitalization, the Company conducted an impairment test of its goodwill and intangible assets as of May 31, 2022. As a result of this testing, the Company recorded a non-cash goodwill impairment charge of $299,705 (equivalent to $4.30 per basic and diluted ​ While management cannot predict if or when additional future goodwill impairments may occur, additional goodwill impairments could have material adverse effects on the Company’s operating income, net assets, and/or the Company’s cost of, or access to, capital. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of May 31, 2022 ​ ​ Useful Life ​ Gross Value ​ Accumulated Amortization ​ Net Carrying Value ​ Weighted Average Remaining Useful Life Customer relationships ​ 2 to 20 years ​ $ 124,050 ​ $ (9,425) ​ $ 114,625 ​ 18.4 Technology ​ 2 to 5 years ​ ​ 111,526 ​ ​ (27,736) ​ ​ 83,790 3.7 Supplier-based network ​ 5 years ​ ​ 25,000 ​ ​ (6,250) ​ ​ 18,750 ​ 3.8 Trade name ​ 10 years ​ ​ 13,700 ​ ​ (1,455) ​ ​ 12,245 8.9 Non-compete agreement ​ 2 to 3 years ​ ​ 9,300 ​ ​ (4,392) ​ ​ 4,908 1.3 ​ ​ ​ ​ $ 283,576 ​ $ (49,258) ​ $ 234,318 ​ ​ ​

Leases

Leases	3 Months Ended
	May 31, 2022
Leases
Leases	(6) Leases The Company adopted Topic 842 on February 28, 2022, with an effective date of adoption of March 1, 2021, using the modified retrospective approach. The Company has operating leases for offices and certain equipment under non-cancelable leases in the United States and Czech Republic. These leases have remaining terms of up to 8 years. The Company had no finance leases during the three months ended May 31, 2022. The components of operating lease cost recorded in the consolidated statements of operations were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended May 31, ​ ​ ​ 2022 ​ ​ 2021 Operating lease cost ​ ​ 1,949 ​ $ 1,760 Variable lease cost ​ ​ 430 ​ ​ 344 Total lease cost ​ ​ 2,379 ​ $ 2,104 ​ The following tables set forth the cash flows, weighted-average remaining term, and weighted-average discount rate for the Company’s leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended May 31, Cash Flow Information ​ 2022 ​ 2021 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 2,128 ​ ​ $ 2,036 ​ Right-of-use assets obtained in exchange for lease obligations ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 2,155 ​ ​ $ 2,367 ​ ​ ​ ​ ​ ​ ​ Supplemental Information ​ ​ May 31, 2022 ​ Weighted-average remaining lease term (years) ​ ​ 5.8 ​ Weighted-average discount rate ​ ​ 4.9 % ​ ​ ​ ​ ​ ​ Year Ending February 28(29), ​ ​ Remainder of 2023 ​ $ 6,667 2024 ​ 8,860 2025 ​ 7,281 2026 ​ 7,248 2027 ​ 6,318 Thereafter ​ 9,405 Total lease payments ​ ​ 45,779 Less: Imputed interest ​ ​ (6,221) Total lease liabilities ​ $ 39,558 ​

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	May 31, 2022
Fair Value Measurements
Fair Value Measurements	(7) Fair Value Measurements The following table sets forth the fair value of the Company’s financial assets and liabilities within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 ​ Level 1 Level 2 Level 3 Fair Value Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalents: ​ ​ ​ ​ Money market funds ​ $ 98,800 ​ $ — ​ $ — $ 98,800 United States treasury bills ​ $ 144,959 ​ $ — ​ $ — ​ $ 144,959 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 ​ Level 1 Level 2 Level 3 Fair Value Assets ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalents: ​ ​ ​ ​ Money market funds ​ $ 131,527 ​ $ — ​ $ — ​ $ 131,527 United States treasury bills ​ $ 99,999 ​ $ — ​ $ — ​ $ 99,999 ​ The estimated fair value of the convertible senior notes (Note 8) was $185,265 as of May 31, 2022, based on quoted market prices of the Company’s instrument in markets that are not active and are classified as Level 2 within the fair value hierarchy. Considerable judgment is necessary to interpret the market data and develop an estimate of the fair value. Accordingly, the estimate is not necessarily indicative of the amount at which this instrument could be purchased, sold, or settled.

Debt

Debt	3 Months Ended
	May 31, 2022
Debt
Debt	(8) Debt (a) Convertible Senior Notes and Capped Call Options Convertible Senior Notes The Notes consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 February 28, 2022 Principal $ 287,500 ​ $ 287,500 Unamortized issuance costs (6,417) ​ (6,834) Net carrying amount $ 281,083 ​ $ 280,666 ​ In March 2021, the Company completed a private convertible note offering, pursuant to an Indenture dated as of March 29, 2021 between the Company and U.S. Bank National Association, as trustee (the Indenture), and issued $287,500 of 0.50% Convertible Senior Notes due 2026 (the Notes) that mature in April 2026, unless earlier converted, redeemed or repurchased. The Notes bear interest at a rate of 0.50% per annum, payable semiannually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021 and are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the Company’s election. The Company incurred costs of $8,428 in connection with the Notes and the capped calls, of which $8,368 was allocated to the Notes and recorded as a debt discount and $60 was allocated to the capped call and recorded directly to additional paid-in capital. Net proceeds from the issuance of Notes were $279,132, and the Company used $34,443 of the net proceeds to pay the costs of the capped call transactions described below. For the three months ended May 31, 2022 and 2021, the Company recorded interest expense of $779 and $553, respectively, of which $417 and $302, respectively, was associated with the amortization of the debt discount. Pursuant to the terms of the Notes, a holder may convert all or any portion of its Notes at its option at any time prior to October 1, 2025 and only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on August 31, 2021, if the last reported sale price of the Company’s common stock for at least 20 trading days during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events. On or after October 1, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. ​ The initial conversion rate is 19.8088 shares of the Company’s common stock per $1 principal amount of Notes (equivalent to an initial conversion price of approximately $50.48 per share of the Company’s common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event or convert its Notes called (or deemed called) for redemption in connection with such notice of redemption, as the case may be. The Company may not redeem the Notes prior to April 6, 2024. On or after April 6, 2024, the Company may redeem for cash all or any portion of the Notes (subject to the partial redemption limitation set forth in the Indenture), at its option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days, including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes. Upon a fundamental change (as defined in the Indenture), holders may, subject to certain exceptions, require the Company to purchase their Notes in whole or in part for cash at a price equal to the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date (as defined in the Indenture). In addition, upon a Make-Whole Fundamental Change (as defined in the Indenture), the Company will, under certain circumstances, increase the applicable conversion rate for a holder that elects to convert its Notes in connection with such Make-Whole Fundamental Change. Under the Indenture, the Notes may be accelerated upon the occurrence of certain customary events of default. If certain bankruptcy and insolvency-related events of default with respect to the Company occur, the principal of, and accrued and unpaid interest on, all of the then outstanding Notes shall automatically become due and payable. The Indenture provides that the sole remedy for an event of default relating to certain failures by the Company to comply with reporting covenants, including timely filings, consists exclusively of the right to receive additional interest on the Notes. As of May 31, 2022, none of the conditions of the Notes to early convert have been met. The Notes are the Company’s senior, unsecured obligations that rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated to the Notes, rank equally in right of payment with the Company’s future senior unsecured indebtedness that is not so subordinated, effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables and preferred equity (to the extent the Company is not a holder thereof)) of the Company’s subsidiaries. The Notes contain both affirmative and negative covenants. As of May 31, 2022, the Company was in compliance with all covenants in the Notes. ​ The Company concluded the Notes are accounted for as debt, with no bifurcation of the embedded conversion feature. Transaction costs were recorded as a direct deduction from the related debt liability in the consolidated balance sheet and are amortized to interest expense using the effective interest method over the term of the Notes. The effective interest rate for the Notes is 1.1%. ​ Capped Call Concurrent with the pricing of the Notes, the Company entered into privately negotiated capped call transactions with two of the initial purchasers and/or their respective affiliates and another financial institution (the Option Counterparties). The capped call transactions are expected to offset the potential dilution to Accolade’s common stock as a result of any conversion of Notes, with such offset subject to a cap initially equal to $76.20 (which represented a premium of 100% over the last reported sale price of the Company’s common stock on March 24, 2021). The capped call transactions are separate transactions, entered into by the Company with the Option Counterparties, and are not part of the terms of the Notes. As the capped call options are both legally detachable and separately exercisable from the Notes, the Company accounts for the capped call options separately from the Notes. The capped call options are indexed to the Company’s own common stock and classified in stockholders’ equity. As such, the premiums paid for the capped call options were included as a net reduction to additional paid-in capital in the consolidated balance sheet (b) Revolving Credit Facility During July 2019, the Company entered into a revolving credit facility (the 2019 Revolver) with a syndicate of two banks. Under the 2019 Revolver, the Company has the capacity to borrow up to $80,000 on a revolving facility. Availability of borrowings on the 2019 Revolver is calculated as a multiple of the Company’s eligible monthly recurring revenues (as defined in the 2019 Revolver). As of May 31, 2022, the Company had outstanding letters of credit to serve as office landlord security deposits in the amount of $1,425. These letters of credit are secured through the revolving credit facility, thus reducing the maximum capacity of the revolving credit facility to $78,575 as of May 31, 2022. No amounts are outstanding as of May 31, 2022. The 2019 Revolver term ends on July 19, 2022. The interest rate on the outstanding borrowings are at LIBOR plus 350 basis points (prior to December 31, 2021) or Base Rate (as defined) plus 250 basis points, with the LIBOR rate and Base Rate subject to minimum levels. Interest payments are to be made in installments of one, two, or three months as chosen by the Company. The Company incurred lender and third-party fees when entering into the 2019 Revolver, all of which were deferred at the onset of the facility. Issuance costs of $543, including the fair value of warrants issued, were capitalized and are being amortized to interest expense over the remainder of the 2019 Revolver term. During the three months ended May 31, 2022 and 2021, the Company recorded interest expense of $52 and $121, respectively, related to the revolving credit facility. As of February 28, 2021, deferred financing fees have been fully amortized. On August 21, 2020, the Company entered into an amendment to the 2019 Revolver which revised the terms of the revenue covenant and imposed minimum LIBOR and Base Rate levels. On September 11, 2020, the Company entered into a second amendment to the 2019 Revolver which modified the allocation requirements of the Company’s cash to be held at each of the two lenders participating in the 2019 Revolver. On November 6, 2020, the Company entered into a third amendment to the 2019 Revolver which increased the capacity from a maximum of $50,000 to a maximum of $80,000, based on the achievement of certain growth metrics as defined in the amendment. On March 2, 2021, the Company entered into a fourth amendment to the 2019 Revolver in association with the acquisition of 2nd.MD to be completed and amended certain revenue covenants. On March 23, 2021, the Company entered into a fifth amendment to the 2019 Revolver in association with the issuance of the Convertible Senior Notes. On May 26, 2021, the Company entered into a sixth amendment to the 2019 Revolver in association with the acquisition of PlushCare which modified certain reporting covenants. The 2019 Revolver is collateralized by substantially all of the assets of the Company.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	May 31, 2022
Stock-based Compensation
Equity-based Compensation	(9) Stock-based Compensation The following table summarizes the amount of stock-based compensation included in the consolidated statements of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended May 31, ​ 2022 2021 Cost of revenue, excluding depreciation and amortization ​ $ 1,128 ​ $ 328 Product and technology ​ 7,490 ​ 1,822 Sales and marketing ​ 3,989 ​ 1,373 General and administrative ​ 6,782 ​ 4,152 Total stock-based compensation ​ $ 19,389 ​ $ 7,675 ​ (a) Stock Options In July 2020, the Company adopted the 2020 Equity Incentive Plan (the Incentive Plan), which authorized the Company to grant up to 4,300,000 shares of common stock to eligible employees, directors, and consultants to the Company in the form of stock options, restricted stock units, and other various equity awards, including any shares subject to stock options or other awards granted under the Company’s prior stock option plan that expire or terminate for any reason (other than being exercised in full) or are cancelled in accordance with the terms of the prior stock option plan. The Incentive Plan also includes an annual evergreen increase, and the amount, terms of grants, and exercisability provisions are determined by the board of directors. The term of an award may be up to 10 years and options generally vest over four years, with one remainder The following is a summary of stock option activity under the Incentive Plan: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ ​ ​ exercise ​ contractual life intrinsic ​ Stock Options ​ price ​ in years ​ value Balance, February 28, 2022 8,045,792 $ 11.24 ​ ​ ​ ​ Granted 87,008 ​ 14.05 ​ Exercised (45,755) ​ 7.28 ​ Forfeited (91,644) ​ 19.84 ​ Balance, May 31, 2022 7,995,401 $ 11.20 5.8 years $ 7,983,093 ​ For the three months ended May 31, 2022 and 2021, the Company recognized $2,692 and $2,114 in compensation expense related to stock options, respectively. As of May 31, 2022, approximately $22,162 of unrecognized compensation expense related to our stock options is expected to be recognized over a weighted average period of 2.1 years. The aggregate intrinsic value of stock options exercised was $349 and $8,774 for the three months ended May 31, 2022 and 2021, respectively. (b) PlushCare Stock Options In connection with the acquisition of PlushCare, the Company assumed all stock options that were awarded under the PlushCare Plan and that were outstanding as of the closing of the acquisition. These options were converted into options to purchase the Company’s common stock at a ratio determined in the purchase agreement. The Company has no intent to grant any further options under the PlushCare Plan beyond the options granted and outstanding as of the Company's acquisition of PlushCare. The following is a summary of stock option activity under the PlushCare Plan: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ ​ ​ exercise ​ contractual life intrinsic ​ Stock Options ​ price ​ in years ​ value Balance, February 28, 2022 267,721 ​ ​ ​ ​ ​ ​ Exercised (24,678) $ 1.06 ​ Forfeited — $ — ​ ​ Balance, May 31, 2022 243,043 $ 1.71 7.5 years $ 1,144,746 ​ There were 48,556 stock options outstanding as of the acquisition date that were exercised prior to being vested. These options are excluded from the table above and vest on a pro rata basis monthly through May 2023. A total of 6,309 options vested during the three months ended May 31, 2022. For the three months ended May 31, 2022, the Company recognized $1,244 in compensation expense related to PlushCare stock options. As of May 31, 2022, approximately $6,086 of unrecognized compensation expense related to PlushCare stock options is expected to be recognized over a weighted average period of 1.7 years. The aggregate intrinsic value of stock options exercised was $260,688 for the three months ended May 31, 2022. (c) Restricted Stock Units The Company issued 622,873 time-based restricted stock units during the three months ended May 31, 2022. These time-based restricted stock units are generally subject to a four-year vesting period, with one quarter of an award vesting one year after the vesting commencement date and the remainder vesting ratably on a monthly basis over the subsequent three years . The following is a summary of activity for the three months ended May 31, 2022: ​ ​ ​ ​ ​ Restricted Stock Units Balance, February 28, 2022 ​ 2,226,057 Granted ​ 622,873 Vested ​ (158,268) Forfeited ​ (111,415) Balance, May 31, 2022 ​ 2,579,247 For the three months ended May 31, 2022 and 2021, the Company recognized $6,632 and $1,630, respectively, in restricted stock unit compensation expense with $75,958 remaining total unrecognized compensation costs related to these awards as of May 31, 2022. The total unrecognized costs are expected to be recognized over a weighted-average term of 3.1 years. The weighted average grant date fair value of restricted stock units granted during the three months ended May 31, 2022 was $14.10. In connection with the PlushCare acquisition, the agreement provides for the issuance of time-based restricted stock units for 64,694 shares of common stock to existing PlushCare shareholders, upon the achievement of the contingent consideration revenue milestones. These restricted stock units have not yet been issued and are not included in the table above. For the three months ended May 31, 2022, the Company recognized $183 in restricted stock unit compensation expense related to these restricted stock units. Also, during the quarter ended May 31, 2022, the Company recorded $1,312 in stock-based compensation expense related to the approved issuance of restricted stock units in lieu of cash for a portion of the Company’s 2023 bonus plan payout. (d) Employee Stock Purchase Plan In July 2020, the Board of Directors adopted the Company’s 2020 Employee Stock Purchase Plan (the ESPP), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering (IPO). The total shares of common stock initially reserved under the ESPP was limited to 1,100,000 shares. On March 1, 2022, there was an automatic annual increase, which increased the total available common shares to . Compensation – Stock Compensation , During the three months ended May 31, 2022 and 2021, employees who elected to participate in the ESPP purchased a total of 343,310 and 50,516 shares of common stock, respectively, resulting in cash proceeds to the Company of $1,787 and $1,948, respectively. ESPP employee payroll contributions accrued as of May 31, 2022 and February 28, 2022 totaled $874 and $1,511, respectively, and are included within accrued compensation in the consolidated balance sheet. Cash withheld via employee payroll deductions is presented in financing activities as proceeds from stock purchases under employee stock purchase plan on the consolidated statement of cash flows. (e) Other In connection with the acquisition of 2nd.MD (Note 4), several 2nd.MD individuals entered into agreements with the Company whereby these individuals are eligible to receive an aggregate of 608,332 shares that required continued employment with the Company. These shares are excluded from the above restricted stock units table. Included in the 608,332 shares are 281,531 shares that were also contingent upon the achievement of the contingent consideration milestones. These shares are considered compensatory in the post business combination periods due to the additional service requirement for these individuals. These shares vested 50% on the first anniversary of the acquisition date and will vest 50% on the second anniversary of acquisition date. As a result of the achievement of certain revenue milestones (the contingent consideration milestones), a total of 256,418 of the eligible 281,531 shares will be issued to such shareholders, subject to the service requirements. As of May 31, 2022, there were 241,614 unvested shares outstanding with a grant date fair value of $46.56 per share, with vesting subject to future service periods. The Company recognized stock-based compensation expense of $3,358 during the three months ended May 31, 2022, including $3,139 of accelerated expense related to certain separation and transition agreements entered into during fiscal 2022. The unamortized compensation expense of $ will be recognized over a weighted average remaining period of 0.7 years. In connection with the acquisition of PlushCare (Note 4), certain PlushCare individuals entered into agreements with the Company whereby these individuals are eligible to receive an aggregate of 806,161 shares that require continued employment with the Company. These shares are excluded from the above restricted stock units table. These shares are considered compensatory in the post business combination periods due to the additional service requirement for these individuals. One third of these shares will vest on the first anniversary of the acquisition date, one third will vest on the second anniversary of acquisition date, and one third will vest on the third anniversary of the acquisition date. As of May 31, 2022, there were 806,161 unvested shares outstanding with a grant date fair value of $52.52 per share. The Company recognized stock-based compensation expense of $3,557 during the three months ended May 31, 2022. The unamortized compensation expense of $28,574 will be recognized over a weighted average remaining period of 2.2 years.

Income Taxes

Income Taxes	3 Months Ended
	May 31, 2022
Income Taxes
Income Taxes	(10) Income Taxes The provision (benefit) for income taxes consists of provisions for federal, state and foreign income taxes for separate U.S. tax filers and for entities in separate tax jurisdictions. As a result of the Company’s history of net operating losses (NOL), the Company has historically provided for a full valuation allowance against its U.S. deferred tax assets that are not more-likely-than-not to be realized. For the three months ended May 31, 2022 and 2021, the Company recorded income tax provision (benefit) of $(3,899) and $19, respectively, which resulted in effective tax rates of 1.1% and (0.0%), respectively. The tax benefit of $(3,899) for the three months ended May 31, 2022 is primarily related to the reversal of the deferred tax liability associated with the basis difference in goodwill from the 2nd.MD acquisition. The goodwill impairment recorded required the Company to reverse that deferred tax liability during the three months ended May 31, 2022.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	May 31, 2022
Net income (Loss) Per Share Attributable to Common Stockholders
Net income (Loss) Per Share Attributable to Common Stockholders	(11) Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to Accolade’s common stockholders: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ ​ May 31, ​ ​ 2022 ​ 2021 Net loss $ (342,822) $ (48,707) Weighted-average common shares used in computing net loss per share ​ ​ 69,738,638 ​ ​ 58,261,233 Net loss per share attributable to common stockholders, basic and diluted ​ $ (4.92) $ (0.84) ​ Contingently issuable securities are excluded from diluted net loss per share attributable to common stockholders until the contingency has been resolved. In the periods in which the Company has reported a net loss, the potentially dilutive securities are antidilutive. The following potential outstanding shares of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ ​ May 31, ​ 2022 2021 Stock options ​ 8,238,444 ​ 8,448,011 Unvested restricted stock units ​ 2,579,247 ​ 501,952 Shares issued to 2nd.MD employees and subject to vesting ​ 274,224 ​ 608,332 Contingent shares in connection with 2nd.MD acquisition ​ — ​ 1,889,441 Shares issued to PlushCare employees and subject to vesting ​ 831,398 ​ — Indemnity shares held in escrow in connection with PlushCare acquisition ​ 27,342 ​ — Shares to be issued to HealthReveal shareholders upon expiration of indemnification ​ 28,089 ​ — Convertible Senior Notes ​ 5,700,297 ​ 5,700,297 Total 17,679,041 17,148,033 ​

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	May 31, 2022
Commitments and Contingencies.
Commitments and Contingencies	(12) Commitments and Contingencies (a) Legal Proceedings The Company is involved in various claims, inquiries and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters is not expected to have a material adverse effect on the Company’s financial position or liquidity. As of May 31, 2022, the Company had accruals of $888 related to legal matters. On May 8, 2021, a purported class action complaint ( Robbins v. PlushCare, Inc. et al. (b) Employment Agreements Certain officers of the Company have employment agreements providing for severance, continuation of benefits, and other specified rights in the event of termination without cause, including in the event of a change of control of the Company, as defined in the agreements. (c) Purchase Obligations The Company has minimum required purchase commitments of $40,323 pursuant to an agreement primarily related to cloud computing services. Portions of the total purchase commitment are required to be met prior to September 30 in each of the fiscal years 2023 through 2027. As of May 31, 2022, the Company has remaining future purchase commitments under this agreement of $36,736. ​

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	May 31, 2022
Basis of Presentation and Summary of Significant Accounting Policies.
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation Accolade’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and include the Company’s accounts and those of the Company’s wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Through the acquisition of PlushCare, Inc. (PlushCare), the Company has various administrative service agreements (ASA) with professional medical corporations established in California, Illinois, Wyoming, and New Jersey (PC). The PCs employ or contract with medical providers who provide services via the Company’s technology platform. The ASAs are evergreen and are terminable by the parties for breach or bankruptcy. Through the ASAs, the Company provides non-clinical administrative services to the PCs and manages the economic activities that most significantly affect PCs. The PCs retain control over the provision of medical services and the PC’s clinical personnel. The PCs are variable interest entities (VIE) to the Company. Under Accounting Standards Codification Subtopic 810 – Consolidation The PCs and the Company are independent entities, and as such creditors of the PCs do not have recourse against the Company in the event of default by the PCs. Additionally, the PCs’ non-cash assets are available to the Company to satisfy obligations or for other corporate purposes.
Unaudited Interim Financial Statements	(b) Unaudited Interim Financial Statements The accompanying consolidated financial statements and the related footnote disclosures are unaudited. The unaudited consolidated interim financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s interim consolidated financial position as of May 31, 2022, the results of its operations for the three months ended May 31, 2022 and 2021, and its cash flows for the three months ended May 31, 2022 and 2021. The results for the three months ended May 31, 2022 are not necessarily indicative of results to be expected for the year ending February 28, 2023, any other interim periods, or any future year or period. The Company’s management believes that the disclosures are adequate to make the information presented not misleading when read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended February 28, 2022.
Capitalized Internal-Use Software Costs	(c) Capitalized Internal-Use Software Costs Costs related to software acquired, developed, or modified solely to meet the Company’s internal requirements, including tools that enable the Company’s employees to interact with members and their providers, with no substantive plans to market such software at the time of development, are capitalized. Costs incurred during the preliminary planning and evaluation stage of the project and during the post-implementation operational stage are expensed as incurred. Costs related to minor upgrades, minor enhancements, and maintenance activities are expensed as incurred. Costs incurred during the application development stage of the project are capitalized. Internal-use software is included in property and equipment and is amortized on a straight-line basis over 3 years. For the three months ended May 31, 2022 and 2021, the Company capitalized $766 and $0, respectively, for internal-use software. Amortization expense related to capitalized internal-use software during the three months ended May 31, 2022 and 2021 was $290 and $1,214, respectively.
Impairment of Long Lived Assets	(d) Impairment of Long-Lived Assets The Company reviews long-lived assets, such as property and equipment and finite-lived intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset. There were no long-lived asset impairment charges recorded during the three months ended May 31, 2022 and 2021.
Intangible Assets	(e) Intangible Assets The Company has acquired intangible assets in the form of developed technology, customer relationships, trade names, supplier-based network, and non-compete agreements through various acquisitions. Intangible assets are recorded at fair value on the date of acquisition and are subject to amortization over the estimated useful lives of each asset. Estimates of fair value and useful lives are based on historical factors, current circumstances, and the experience and judgment of management. Estimates and assumptions used to value intangible assets are evaluated by management on an ongoing basis.
Goodwill	(f) Goodwill Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit. The Company performs its annual goodwill impairment test on an annual basis in the fourth quarter of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded. A goodwill impairment loss was recorded during the three months ended May 31, 2022. See Note 5 for further information.
Revenue and Deferred Revenue	( g ) Revenue and Deferred Revenue Revenue Recognition The Company generates revenue by providing customers access to its advocacy, expert medical opinion, and virtual primary care and mental health support services, as well as through utilization of its expert medical opinion and virtual primary care and mental health support services that were acquired through the acquisitions of Innovation Specialists LLC d/b/a 2nd.MD (2nd.MD) and PlushCare. Contracts with customers that include expert medical opinion or virtual primary care and mental health support services may contain either an access fee, a utilization-based fee, or both. In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers ● identification of the contract, or contracts with a customer; ● identification of the performance obligations in the contract; ● determination of the transaction price; ● allocation of the transaction price to the performance obligations in the contracts; and ● recognition of revenue when, or as, the Company satisfies a performance obligation. At contract inception, the Company assesses the type of services being provided and assesses the performance obligations in the contract. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on overall pricing objectives, taking into consideration market conditions and other factors, using an expected cost plus margin approach. The Company considered the variable consideration allocation exception in ASC 606 for its advocacy contracts and concluded that such exception for allocating variable consideration to distinct performance obligations or distinct time periods within a series was not met primarily due to variability in its per-member-per-month (PMPM) pricing. The majority of fees earned by the Company are considered to be variable consideration due to both the uncertainty regarding the total number of members, consultations or visits for which the Company will invoice the customer, as well as the variable PMPM fees that are dependent upon the achievement of performance metrics and/or healthcare cost savings. Performance metrics are measured monthly, quarterly, or annually, and with respect to the achievement of healthcare cost savings targets, annually (typically measured on a calendar year basis). Accordingly, at contract inception and on an ongoing basis, as part of the Company’s estimate of the transaction price, the Company determines whether any such fees should be constrained, and the Company includes the estimated consideration for those fees to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur (and is therefore considered to be unconstrained). Consideration related to the Company’s achievement of healthcare cost savings is typically constrained until the end of the applicable calendar year due to uncertainty related to factors outside of the Company’s control. Consideration related to other performance metrics is typically not constrained based on the Company’s prior success of achieving such metrics. On an ongoing basis, the Company reassesses its estimates for variable consideration, which can change based upon its assessment of the achievement of performance metrics and healthcare cost savings, as well as the number of members, consultations, or visits. Access Fees The Company generates revenue primarily from contracts with customers to access the Company’s advocacy, expert medical opinion, and virtual primary care and mental health support services. The Company prices access fees primarily using a recurring PMPM fee, typically with a portion of the fee calculated as the product of a fixed rate times the number of members (fixed PMPM fee), plus a variable PMPM fee calculated as the product of a variable rate times the number of members (variable PMPM fee). The fees associated with the variable PMPM fee can be earned through the achievement of performance metrics and/or the realization of healthcare cost savings resulting from use of the Company’s services. Collectively, the fixed PMPM fee and variable PMPM fee are referred to as the total PMPM fee. The Company’s PMPM pricing varies by contract. In certain contracts, the maximum total PMPM fee varies during the contract term (total PMPM rate increases or decreases annually), while in other contracts, the total PMPM maximum fee is consistent over the term, yet the fixed and variable portions vary. For example, in certain contracts the fixed PMPM fee increases on an annual basis while the variable PMPM fee decreases on an annual basis, resulting in the same total PMPM fee throughout the term of the contract. The PMPM fees for expert medical opinion and virtual primary care and mental health support services may be tiered based upon the customer’s utilization. Access to the Company’s services represent a single stand-ready performance obligation. The Company’s contracts include stand-ready services to provide eligible participants with access to the Company’s services and to perform an unspecified quantity of interactions with members during the contract period. Accordingly, the Company’s services are generally viewed as stand-ready performance obligations comprised of a series of distinct daily services that are substantially the same and have the same pattern of transfer. For advocacy services, the Company satisfies these performance obligations over time and recognizes revenue related to its services as the services are provided using a measure of progress based upon the actual number of members eligible for the service during the respective period as a percentage of the estimated members expected to be eligible for the service over the term of the contract. The Company believes a measure of progress based on the number of members is the most appropriate measurement of control of the services being transferred to the customer as the amount of internal resources necessary to stand-ready is directly correlated to the number of members who can use the services. For the majority of expert medical opinion services, the Company satisfies these performance obligations over time and recognizes revenue in the amount of consideration for which it has the right to invoice using the as-invoiced practical expedient. Access fees also include access to the Company’s virtual primary care and mental health support services sold directly to consumers on a monthly or yearly fixed fee subscription basis. For these services, the Company satisfies these stand-ready performance obligations over time and recognizes revenue ratably over the subscription period. Utilization-based fees The Company also generates revenue when members utilize the expert medical opinion and virtual primary care and mental health support services that are billed based on utilization. Many, but not all, contracts with customers contain utilization-based fees. For any utilization-based fees, the Company satisfies these performance obligations over time and recognizes revenue in the amount of consideration for which it has the right to invoice using the as-invoiced practical expedient for any consultations or visits sold to enterprise customers as well as any non-insured consultations or visits related to virtual primary care and mental health support services sold directly to consumers. For any consultations or visits that are paid through insurance claims, the Company recognizes revenue as the consultations and visits occur in an amount that reflects the consideration that is expected based upon then-current prices and historical experience from insurance payors. Deferred Revenue The Company typically invoices its customers in advance of the services performed on a monthly or quarterly basis, and the amount invoiced typically represents the maximum total PMPM fee for the estimated number of eligible members over the applicable invoice period. The total PMPM fee covers the stand-ready services in the Company’s typical contracts (i.e., the performance obligations are not separately priced or invoiced). The maximum total PMPM fee that is invoiced includes both the fixed PMPM fee and the variable PMPM fee related to the performance metrics and/or the realization of healthcare cost savings that can be achieved during the period. These fees are classified as deferred revenue on the Company’s consolidated balance sheet until such time that revenue can be recognized. In the event the Company fails to satisfy any of the performance metrics and/or realization of healthcare cost savings that are billed in advance, the Company will refund the applicable portion of the fee or offset the amount against a future invoice. These amounts are included in due to customers on the Company’s consolidated balance sheet. The Company’s accounts receivable represent rights to consideration that are unconditional.
Concentration of Credit Risk	( h ) Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and marketable securities. The Company maintains its cash primarily with domestic financial institutions of high credit quality, which may exceed federal deposit insurance corporation limits. The Company invests its cash equivalents in highly rated money market funds. Marketable securities are comprised of United States treasury bills with original maturities greater than 90 days. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions. Significant customers are those which represent 10% or more of the Company’s revenue during the periods. For each significant customer, revenue as a percentage of total revenue was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended May 31, ​ ​ 2022 2021 ​ Customer 1 * % 11.9 % ​ *For the three months ended May 31, 2022, no customer represented 10% or more of the Company’s revenue.
Marketable securities	( i ) Marketable Securities The Company classifies its marketable securities as available-for-sale, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair market value.
Leases	(j) Leases In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases The Company adopted Topic 842 on February 28, 2022, with an effective date of adoption of March 1, 2021, using the modified retrospective approach. Topic 842 requires the Company to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on its consolidated balance sheet for most leases and disclose key information about leasing arrangements. The Company elected to utilize the package of practical expedients available under Topic 842, which allowed it to not reassess: (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases, and (iii) the initial direct costs for existing leases. As a result of the adoption, the Company recorded operating lease right-of-use assets and operating lease liabilities of $34,739 and $38,740, respectively, on the consolidated balance sheet as of March 1, 2021. Whenever the Company enters into a new arrangement, it determines, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the right to direct the use of, and obtain substantially all the economic benefits from, the use of the underlying asset. If a lease exists, the Company then determines the separate lease and non-lease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect, and is not significantly affected by, other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered non-lease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and non-lease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and non-lease components. For each lease, the Company then determines the lease term, the present value of lease payments, and the classification of the lease as either an operating or finance lease. The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor. ​ The present value of lease payments is calculated based on: ​ (1) Lease payments – Lease payments included in the measurement of the lease asset or liability comprise the following: fixed payments (including in-substance fixed payments), and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise. ​ (2) Discount rate – the discount rate is determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term. In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee’s and lessor’s rights, obligations, and economic incentives over the term of the lease. The Company does not recognize leases with an initial term of 12 months or less on its consolidated balance sheets and will recognize these payments in the consolidated statements of operations on a straight-line basis over the lease term. Certain leases contain variable payments which are based on usage or operating costs, such as utilities and maintenance. These payments are not included in the measurement of the lease liability or corresponding right-of-use asset due to the uncertainty of the payment amount and are recorded as lease expense in the period incurred. Prior to the adoption of Topic 842, the Company accounted for leases under FASB ASC Topic 840, Leases

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	May 31, 2022
Revenue [Member] | Customer Concentration Risk
Concentration Risk [Line Items]
Schedule of concentration of risk	​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended May 31, ​ ​ 2022 2021 ​ Customer 1 * % 11.9 % ​ *For the three months ended May 31, 2022, no customer represented 10% or more of the Company’s revenue.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	May 31, 2022
Revenue
Disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended May 31, ​ 2022 2021 Access fees $ 68,125 ​ $ 56,205 Utilization-based fees 17,403 ​ 3,322 Total $ 85,528 ​ $ 59,527
Revenue expected to be recognized from remaining performance obligations	​ ​ ​ ​ Fiscal year ending February 28(29), ​ ​ Remainder of 2023 $ 127,326 2024 73,836 2025 39,813 2026 2,769 Total $ 243,744

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	May 31, 2022
Business Acquisition [Line Items]
Schedule of proforma results	​ ​ ​ ​ ​ ​ ​ Unaudited Pro Forma ​ ​ Three months ended May 31, 2021 Revenue ​ $ 72,532 Net loss ​ $ (63,099)
Acquisition of 2nd.MD
Business Acquisition [Line Items]
Schedule of purchase consideration	​ ​ ​ ​ ​ Consideration ​ Cash consideration, net of cash acquired ​ $ 226,135 Fair value of common stock issued ​ 116,187 Fair value of replacement awards ​ ​ 1,520 Fair value of contingent consideration ​ 76,248 Total consideration ​ $ 420,090
Schedule of estimated fair values of the assets acquired and liabilities assumed	​ ​ ​ ​ ​ Assets acquired: ​ Accounts receivable ​ $ 5,550 Unbilled revenue ​ ​ 226 Current portion of deferred contract acquisition costs ​ ​ 176 Prepaid and other current assets ​ 1,052 Property and equipment ​ ​ 4,344 Deferred contract acquisition costs ​ ​ 564 Goodwill ​ 208,286 Intangible assets (1) ​ ​ Customer relationships ​ ​ 120,000 Technology ​ ​ 58,000 Supplier-based network ​ ​ 25,000 Trade name ​ ​ 3,400 Non-compete agreement ​ ​ 3,100 Total assets acquired ​ $ 429,698 ​ ​ Liabilities assumed: ​ Accounts payable ​ $ 1,195 Accrued expenses ​ ​ 585 Accrued compensation ​ ​ 3,817 Deferred rent and other current liabilities ​ 904 Due to customers ​ ​ 294 Current portion of deferred revenue ​ ​ 625 Deferred rent and other noncurrent liabilities ​ ​ 2,188 Total liabilities assumed ​ $ 9,608 ​ ​ Net assets acquired ​ $ 420,090 (1) The weighted-average useful life of intangible assets acquired is approximately 14 years .
PlushCare
Business Acquisition [Line Items]
Schedule of purchase consideration	​ ​ ​ ​ ​ Consideration ​ Fair value of common stock issued ​ $ 330,338 Fair value of contingent consideration ​ 44,618 Cash consideration, net of cash acquired ​ ​ 33,860 Fair value of replacement awards ​ ​ 5,209 Total consideration ​ $ 414,025
Schedule of estimated fair values of the assets acquired and liabilities assumed	​ ​ ​ ​ ​ Assets acquired: ​ Accounts receivable ​ $ 1,359 Prepaid and other current assets ​ 573 Property and equipment ​ ​ 298 Other noncurrent assets ​ ​ 932 Goodwill ​ 365,597 Intangible assets (1) ​ ​ Customer relationships ​ ​ 4,050 Technology ​ ​ 40,650 Trade name ​ ​ 10,300 Non-compete agreements ​ ​ 6,200 Total assets acquired ​ $ 429,959 ​ ​ Liabilities assumed: ​ Accounts payable ​ $ 1,532 Accrued expenses ​ ​ 193 Accrued compensation ​ ​ 2,117 Current portion of deferred revenue ​ ​ 1,212 Deferred tax liability ​ ​ 9,992 Other liabilities ​ ​ 888 Total liabilities assumed ​ $ 15,934 ​ ​ Net assets acquired ​ $ 414,025 (1) The weighted-average useful life of intangible assets acquired is approximately 5 years . ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	May 31, 2022
Goodwill and Intangible Assets
Schedule of changes in the carrying amount of goodwill	​ ​ ​ ​ ​ Balance, February 28, 2022 ​ $ 577,896 Impairment ​ ​ (299,705) Balance, May 31, 2022 ​ $ 278,191
Schedule of Intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of May 31, 2022 ​ ​ Useful Life ​ Gross Value ​ Accumulated Amortization ​ Net Carrying Value ​ Weighted Average Remaining Useful Life Customer relationships ​ 2 to 20 years ​ $ 124,050 ​ $ (9,425) ​ $ 114,625 ​ 18.4 Technology ​ 2 to 5 years ​ ​ 111,526 ​ ​ (27,736) ​ ​ 83,790 3.7 Supplier-based network ​ 5 years ​ ​ 25,000 ​ ​ (6,250) ​ ​ 18,750 ​ 3.8 Trade name ​ 10 years ​ ​ 13,700 ​ ​ (1,455) ​ ​ 12,245 8.9 Non-compete agreement ​ 2 to 3 years ​ ​ 9,300 ​ ​ (4,392) ​ ​ 4,908 1.3 ​ ​ ​ ​ $ 283,576 ​ $ (49,258) ​ $ 234,318 ​ ​

Leases (Tables)

Leases (Tables)	3 Months Ended
	May 31, 2022
Leases
Schedule of components of operating lease cost	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended May 31, ​ ​ ​ 2022 ​ ​ 2021 Operating lease cost ​ ​ 1,949 ​ $ 1,760 Variable lease cost ​ ​ 430 ​ ​ 344 Total lease cost ​ ​ 2,379 ​ $ 2,104
Schedule of cash flow and supplemental information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended May 31, Cash Flow Information ​ 2022 ​ 2021 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 2,128 ​ ​ $ 2,036 ​ Right-of-use assets obtained in exchange for lease obligations ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 2,155 ​ ​ $ 2,367 ​ ​ ​ ​ ​ ​ ​ Supplemental Information ​ ​ May 31, 2022 ​ Weighted-average remaining lease term (years) ​ ​ 5.8 ​ Weighted-average discount rate ​ ​ 4.9 %
Summary of future aggregate minimum lease payments as of under all non-cancelable operating leases	​ ​ ​ ​ ​ Year Ending February 28(29), ​ ​ Remainder of 2023 ​ $ 6,667 2024 ​ 8,860 2025 ​ 7,281 2026 ​ 7,248 2027 ​ 6,318 Thereafter ​ 9,405 Total lease payments ​ ​ 45,779 Less: Imputed interest ​ ​ (6,221) Total lease liabilities ​ $ 39,558

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	May 31, 2022
Fair Value Measurements
Schedule of fair value of financial assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 ​ Level 1 Level 2 Level 3 Fair Value Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalents: ​ ​ ​ ​ Money market funds ​ $ 98,800 ​ $ — ​ $ — $ 98,800 United States treasury bills ​ $ 144,959 ​ $ — ​ $ — ​ $ 144,959 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 ​ Level 1 Level 2 Level 3 Fair Value Assets ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalents: ​ ​ ​ ​ Money market funds ​ $ 131,527 ​ $ — ​ $ — ​ $ 131,527 United States treasury bills ​ $ 99,999 ​ $ — ​ $ — ​ $ 99,999 ​

Debt (Tables)

Debt (Tables)	3 Months Ended
	May 31, 2022
Debt
Schedule Of Debt	​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 February 28, 2022 Principal $ 287,500 ​ $ 287,500 Unamortized issuance costs (6,417) ​ (6,834) Net carrying amount $ 281,083 ​ $ 280,666

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	May 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock-based compensation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended May 31, ​ 2022 2021 Cost of revenue, excluding depreciation and amortization ​ $ 1,128 ​ $ 328 Product and technology ​ 7,490 ​ 1,822 Sales and marketing ​ 3,989 ​ 1,373 General and administrative ​ 6,782 ​ 4,152 Total stock-based compensation ​ $ 19,389 ​ $ 7,675
Schedule of restricted stock units activity	​ ​ ​ ​ ​ Restricted Stock Units Balance, February 28, 2022 ​ 2,226,057 Granted ​ 622,873 Vested ​ (158,268) Forfeited ​ (111,415) Balance, May 31, 2022 ​ 2,579,247
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock option activity	The following is a summary of stock option activity under the Incentive Plan: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ ​ ​ exercise ​ contractual life intrinsic ​ Stock Options ​ price ​ in years ​ value Balance, February 28, 2022 8,045,792 $ 11.24 ​ ​ ​ ​ Granted 87,008 ​ 14.05 ​ Exercised (45,755) ​ 7.28 ​ Forfeited (91,644) ​ 19.84 ​ Balance, May 31, 2022 7,995,401 $ 11.20 5.8 years $ 7,983,093
PlushCare, Inc. Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock option activity	In connection with the acquisition of PlushCare, the Company assumed all stock options that were awarded under the PlushCare Plan and that were outstanding as of the closing of the acquisition. These options were converted into options to purchase the Company’s common stock at a ratio determined in the purchase agreement. The Company has no intent to grant any further options under the PlushCare Plan beyond the options granted and outstanding as of the Company's acquisition of PlushCare. The following is a summary of stock option activity under the PlushCare Plan: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ ​ ​ exercise ​ contractual life intrinsic ​ Stock Options ​ price ​ in years ​ value Balance, February 28, 2022 267,721 ​ ​ ​ ​ ​ ​ Exercised (24,678) $ 1.06 ​ Forfeited — $ — ​ ​ Balance, May 31, 2022 243,043 $ 1.71 7.5 years $ 1,144,746

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	May 31, 2022
Net income (Loss) Per Share Attributable to Common Stockholders
Schedule of computation of basic and diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ ​ May 31, ​ ​ 2022 ​ 2021 Net loss $ (342,822) $ (48,707) Weighted-average common shares used in computing net loss per share ​ ​ 69,738,638 ​ ​ 58,261,233 Net loss per share attributable to common stockholders, basic and diluted ​ $ (4.92) $ (0.84)
Schedule of common stock were excluded from the computation of diluted net loss per share attributable to common stockholders	​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ ​ May 31, ​ 2022 2021 Stock options ​ 8,238,444 ​ 8,448,011 Unvested restricted stock units ​ 2,579,247 ​ 501,952 Shares issued to 2nd.MD employees and subject to vesting ​ 274,224 ​ 608,332 Contingent shares in connection with 2nd.MD acquisition ​ — ​ 1,889,441 Shares issued to PlushCare employees and subject to vesting ​ 831,398 ​ — Indemnity shares held in escrow in connection with PlushCare acquisition ​ 27,342 ​ — Shares to be issued to HealthReveal shareholders upon expiration of indemnification ​ 28,089 ​ — Convertible Senior Notes ​ 5,700,297 ​ 5,700,297 Total 17,679,041 17,148,033

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Basis of Presentation and Principles of Consolidation (Details) - USD ($) $ in Thousands	May 31, 2022	Feb. 28, 2022
Basis of Presentation and Summary of Significant Accounting Policies
Assets	$ 944,454	$ 1,285,529
Cash	335,628	365,853
Accounts receivable	21,739	21,116
Liabilities	409,947	$ 429,735
PC
Basis of Presentation and Summary of Significant Accounting Policies
Assets	15,491
Cash	12,097
Accounts receivable	2,393
Liabilities	$ 13,661

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Property and Equipment and Capitalized Internal Use Software Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Property, Plant and Equipment [Line Items]
Amortization expenses	$ 11,576	$ 8,696
Computer software
Property, Plant and Equipment [Line Items]
Useful life	3 years
Capitalized cost	$ 766	0
Amortization expenses	$ 290	$ 1,214

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)	3 Months Ended
	May 31, 2021
Customer Concentration Risk | Revenue [Member] | Customer 1
Concentration Risk [Line Items]
Revenue (as a percent)	11.90%

Basis of Presentation and Sum_7

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021	Feb. 28, 2022	Mar. 01, 2021
Impairment of Long Lived Assets
Impairment charges	$ 0	$ 0
Operating lease right-of-use assets	33,790		$ 33,126	$ 34,739
Operating lease liabilities	$ 39,558			$ 38,740

Revenue - Revenues disaggregate

Revenue - Revenues disaggregated (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 85,528	$ 59,527
Access Fees [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	68,125	56,205
Utilization-Based Fees [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ 17,403	$ 3,322

Revenue - Revenue and Deferred

Revenue - Revenue and Deferred Revenue (Details) $ in Thousands	May 31, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue	$ 243,744
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-06-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue	$ 127,326
Revenue remaining performance obligation satisfaction period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue	$ 73,836
Revenue remaining performance obligation satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-03-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue	$ 39,813
Revenue remaining performance obligation satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-03-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue	$ 2,769
Revenue remaining performance obligation satisfaction period	1 year

Revenue - Revenue and Deferre_2

Revenue - Revenue and Deferred Revenue Narratives (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Revenue
Contract with customer liability revenue recognized	$ 24,447	$ 18,925
Revenue related to performance obligations satisfied in prior periods	$ 1,829	$ 1,410

Revenue - Cost to obtain and fu

Revenue - Cost to obtain and fulfill a contract (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Capitalized Contract Cost [Line Items]
Deferred amortization term	5 years
Impairment loss on deferred commission	$ 0	$ 0
Selling and Marketing Expense [Member]
Capitalized Contract Cost [Line Items]
Amortization of contract cost	592	438
Sales commission
Capitalized Contract Cost [Line Items]
Amortization of contract cost	$ 838	427
Customer set up cost
Capitalized Contract Cost [Line Items]
Deferred amortization term	5 years
Amortization of contract cost	$ 225	164
Deferred Implementation Costs [Member]
Capitalized Contract Cost [Line Items]
Amortization of contract cost	$ 86	$ 81

Acquisitions - Summary of Purch

Acquisitions - Summary of Purchase Consideration (Details) - USD ($) $ in Thousands			3 Months Ended
	Jun. 09, 2021	Mar. 03, 2021	May 31, 2021
Consideration Paid
Cash consideration, net of cash acquired			$ 228,013
Acquisition of 2nd.MD
Consideration Paid
Cash consideration, net of cash acquired		$ 226,135
Fair value of common stock issued		116,187
Fair value of replacement awards		1,520
Fair value of contingent consideration		76,248
Total consideration paid		$ 420,090
PlushCare
Consideration Paid
Cash consideration, net of cash acquired	$ 33,860
Fair value of common stock issued	330,338
Fair value of replacement awards	5,209
Fair value of contingent consideration	44,618
Total consideration paid	$ 414,025

Acquisitions - Shares Issued (D

Acquisitions - Shares Issued (Details) $ in Thousands					1 Months Ended	3 Months Ended
	Jun. 01, 2022 shares	Sep. 30, 2021 shares	Jun. 09, 2021 USD ($) employee shares	Mar. 03, 2021 USD ($) item shares	May 31, 2022 USD ($) shares	May 31, 2022 USD ($) shares	May 31, 2021 USD ($)	Feb. 28, 2022 USD ($)	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Revenue							$ 72,532
Net income (loss)							(63,099)
Acquisition related cost						$ 8,380
Goodwill					$ 278,191	278,191		$ 577,896
Net Income (Loss) Attributable to Parent						$ (342,822)	(48,707)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability							$ 10,460
Employees
Business Acquisition [Line Items]
Estimated fair value of replacement awards attributable to pre-acquisition services				$ 5,434
Acquisition of 2nd.MD
Business Acquisition [Line Items]
Aggregate purchase price consideration				420,090
Cash consideration				226,135
Cash acquired				$ 205
Shares issued | shares				2,822,242	1,939,853
Shares Fully Vested Upon Acquisition | shares				2,495,441
Shares Fully Unvested Upon Acquisition | shares				326,801
Number of earnout scenarios | item				2
Estimated fair value of replacement awards attributable to pre-acquisition services				$ 1,520
Units issued | shares				120,760
Estimated fair value of replacement awards				$ 3,914
Fair value of contingent consideration									$ 37,767
Business Combination Acquisition, Cash Consideration, Repayment Of Debt				13,026
Goodwill				208,286
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable				$ 116,187
Acquisition of 2nd.MD | Measurement Input Attrition Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input						8
Acquisition of 2nd.MD | Measurement Input Tax Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input						24
Acquisition of 2nd.MD | Measurement Input, Discount Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input						13
Acquisition of 2nd.MD | Measurement Input Royalty Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input						1.5
Acquisition of 2nd.MD | Measurement Input Probability of Completion Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input						33
Acquisition of 2nd.MD | Individuals Agreements With Company [Member]
Business Acquisition [Line Items]
Shares Fully Unvested Upon Acquisition | shares						326,801
Additional Shares Eligible To Be Received By Individuals Of Company, Upon Achievement Of Contingent Consideration Milestones | shares						281,531
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						2 years
Acquisition of 2nd.MD | Minimum
Business Acquisition [Line Items]
Amortization period						3 years
Acquisition of 2nd.MD | Maximum
Business Acquisition [Line Items]
Shares issued | shares				4,384,882		1,977,343
Additional shares issued | shares				2,170,972
Amortization period						20 years
PlushCare
Business Acquisition [Line Items]
Aggregate purchase price consideration			$ 414,025
Cash acquired			$ 17,837
Shares issued | shares			7,144,393
Estimated fair value of replacement awards attributable to pre-acquisition services			$ 5,209
Units issued | shares			325,992
Estimated fair value of replacement awards			$ 11,454
Fair value of contingent consideration										$ 37,683
Business Combination Acquisition, Cash Consideration, Repayment Of Debt			1,463
Goodwill			$ 365,597
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited | shares			806,161
Number of employees received unvested common stock | employee			1
Stock Issued During Period, Shares, New Issues | shares			48,556
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			$ 330,338
Business Combination, Shares Issued Subject to Future Vesting | shares			854,717
Business Combination Cash Issued Upon Achievement Of Defined Revenue Milestones Following Closing			$ 2,000
Business Combination Additional Shares Issuable Shares | shares	1,327,445		1,429,556
Additional Shares Issuable Withheld | shares	102,111		102,111
PlushCare | Measurement Input, Discount Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input			12.5
PlushCare | Measurement Input Royalty Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input			3
PlushCare | Employees
Business Acquisition [Line Items]
Estimated fair value of replacement awards attributable to pre-acquisition services			$ 16,663
PlushCare | Minimum
Business Acquisition [Line Items]
Amortization period			2 years
PlushCare | Minimum | Measurement Input Attrition Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input			25
PlushCare | Minimum | Measurement Input Tax Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input			25
PlushCare | Minimum | Measurement Input Probability of Completion Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input			70
PlushCare | Maximum
Business Acquisition [Line Items]
Amortization period			10 years
PlushCare | Maximum | Measurement Input Attrition Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input			50
PlushCare | Maximum | Measurement Input Probability of Completion Rate [Member]
Business Acquisition [Line Items]
Fair Value of Intangible Assets, Measurement Input			90
HealthReveal
Business Acquisition [Line Items]
Business Combination, Shares Issued Subject to Future Vesting | shares		28,089
Business Combination Additional Shares Issuable Shares | shares		252,808

Acquisitions - Summary of Estim

Acquisitions - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands				12 Months Ended
	Sep. 30, 2021	Jun. 09, 2021	Mar. 03, 2021	Feb. 28, 2022	May 31, 2022
Assets acquired:
Goodwill				$ 577,896	$ 278,191
PlushCare
Assets acquired:
Accounts receivable		$ 1,359
Prepaid and other current assets		573
Property and equipment		298
Other noncurrent assets		932
Goodwill		365,597
Other assets		932
Total assets acquired		429,959
Liabilities assumed
Accounts payable		1,532
Accrued expenses		193
Accrued compensation		2,117
Current portion of deferred revenue		1,212
Deferred tax liability		9,992
Other long-term liabilities		888
Total liabilities assumed		15,934
Net assets acquired, including contingent consideration		$ 414,025
Weighted-average useful life of intangible assets		5 years
Decrease in recognized goodwill		$ 1,685
PlushCare | Customer relationships
Assets acquired:
Intangible assets		4,050
PlushCare | Technology
Assets acquired:
Intangible assets		40,650
PlushCare | Trade name
Assets acquired:
Intangible assets		10,300
PlushCare | Non-compete agreement
Assets acquired:
Intangible assets		$ 6,200
Acquisition of 2nd.MD
Assets acquired:
Accounts receivable			$ 5,550
Unbilled revenue			226
Current portion of deferred contract acquisition costs			176
Prepaid and other current assets			1,052
Property and equipment			4,344
Deferred contract acquisition costs			564
Goodwill			208,286
Total assets acquired			429,698
Liabilities assumed
Accounts payable			1,195
Accrued expenses			585
Accrued compensation			3,817
Deferred rent and other current liabilities			904
Due to customer			294
Current portion of deferred revenue			625
Deferred rent and other noncurrent liabilities			2,188
Total liabilities assumed			9,608
Net assets acquired, including contingent consideration			$ 420,090
Weighted-average useful life of intangible assets			14 years
Decrease in recognized goodwill				$ 1,878
Acquisition of 2nd.MD | Customer relationships
Assets acquired:
Intangible assets			$ 120,000
Acquisition of 2nd.MD | Technology
Assets acquired:
Intangible assets			58,000
Acquisition of 2nd.MD | Supplier-based network
Assets acquired:
Intangible assets			25,000
Acquisition of 2nd.MD | Trade name
Assets acquired:
Intangible assets			3,400
Acquisition of 2nd.MD | Non-compete agreement
Assets acquired:
Intangible assets			$ 3,100
HealthReveal | Technology
Assets acquired:
Intangible assets	$ 9,976
Liabilities assumed
Weighted-average useful life of intangible assets	3 years

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Carrying amount of goodwill (Details) $ in Thousands	3 Months Ended
	May 31, 2022 USD ($)
Changes in the carrying amount of goodwill
Balance, February 28, 2022	$ 577,896
Impairment	(299,705)
Balance, May 31, 2022	$ 278,191

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	May 31, 2022 USD ($) $ / shares
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment	$ 299,705
Goodwill impairment charge, basic (in dollars per share) | $ / shares	$ 4.30
Goodwill impairment charge, diluted (in dollars per share) | $ / shares	$ 4.30
Impairment charges on intangible assets	$ 0
Discount rate for goodwill impairment test	11%
Goodwill impairment test for current revenue	1.1
Goodwill impairment test for deferred revenue	1.8
Excess of reporting unit fair value over carrying value	$ 0
Income-based approach
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment test, percentage	70%
Market-based approach
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment test, percentage	30%

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Goodwill and Intangible Assets
Gross Value	$ 283,576
Accumulated Amortization	(49,258)
Net Carrying Value	234,318
Amortization expense for intangible assets	10,372	$ 6,605
Customer relationships
Goodwill and Intangible Assets
Gross Value	124,050
Accumulated Amortization	(9,425)
Net Carrying Value	$ 114,625
Weighted Average Remaining Useful Life	18 years 4 months 24 days
Customer relationships | Minimum
Goodwill and Intangible Assets
Useful Life	2 years
Customer relationships | Maximum
Goodwill and Intangible Assets
Useful Life	20 years
Technology
Goodwill and Intangible Assets
Gross Value	$ 111,526
Accumulated Amortization	(27,736)
Net Carrying Value	$ 83,790
Weighted Average Remaining Useful Life	3 years 8 months 12 days
Technology | Minimum
Goodwill and Intangible Assets
Useful Life	2 years
Technology | Maximum
Goodwill and Intangible Assets
Useful Life	5 years
Supplier-based network
Goodwill and Intangible Assets
Useful Life	5 years
Gross Value	$ 25,000
Accumulated Amortization	(6,250)
Net Carrying Value	$ 18,750
Weighted Average Remaining Useful Life	3 years 9 months 18 days
Trade name
Goodwill and Intangible Assets
Useful Life	10 years
Gross Value	$ 13,700
Accumulated Amortization	(1,455)
Net Carrying Value	$ 12,245
Weighted Average Remaining Useful Life	8 years 10 months 24 days
Non-compete agreement
Goodwill and Intangible Assets
Gross Value	$ 9,300
Accumulated Amortization	(4,392)
Net Carrying Value	$ 4,908
Weighted Average Remaining Useful Life	1 year 3 months 18 days
Non-compete agreement | Minimum
Goodwill and Intangible Assets
Useful Life	2 years
Non-compete agreement | Maximum
Goodwill and Intangible Assets
Useful Life	3 years

Leases - Components of operatin

Leases - Components of operating lease cost (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Operating lease cost	$ 1,949	$ 1,760
Variable lease cost	430	344
Total lease cost	$ 2,379	$ 2,104
Maximum
Remaining lease term	8 years

Leases - Cash Flow and Suppleme

Leases - Cash Flow and Supplemental Information (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Leases
Operating cash flows from operating leases	$ 2,128	$ 2,036
Right-of-use assets obtained in exchange for lease obligations	$ 2,155	$ 2,367
Weighted-average remaining lease term (years)	5 years 9 months 18 days
Weighted-average discount rate	4.90%

Leases - Future minimum lease p

Leases - Future minimum lease payments (Details) - USD ($) $ in Thousands	May 31, 2022	Mar. 01, 2021
Leases
Remainder of 2023	$ 6,667
2024	8,860
2025	7,281
2026	7,248
2027	6,318
Thereafter	9,405
Total lease payments	45,779
Less: Imputed interest	(6,221)
Operating lease liabilities	$ 39,558	$ 38,740

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	May 31, 2022	Feb. 28, 2022
Marketable Securities [Abstract]
Convertible senior notes	$ 185,265
Money Market Funds
Cash equivalents:
Fair value	98,800	$ 131,527
Money Market Funds | Level 1
Cash equivalents:
Fair value	98,800	131,527
United States treasury bills
Marketable Securities [Abstract]
Fair value	144,959	99,999
United States treasury bills | Level 1
Marketable Securities [Abstract]
Fair value	$ 144,959	$ 99,999

Debt - Notes (Details)

Debt - Notes (Details) - Convertible Senior Notes - USD ($) $ in Thousands	May 31, 2022	Feb. 28, 2022
Debt Instrument [Line Items]
Principal	$ 287,500	$ 287,500
Unamortized issuance costs	(6,417)	(6,834)
Net carrying amount	$ 281,083	$ 280,666

Debt (Details)

Debt (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2021 USD ($) D $ / shares	May 31, 2022 USD ($) $ / shares	May 31, 2021 USD ($) $ / derivative	Feb. 28, 2022 USD ($)	Nov. 06, 2020 USD ($)	Jul. 31, 2019 USD ($)
Debt Instrument [Line Items]
Long-term Line of Credit		$ 1,425
Repayment of accrued interest in kind		$ 419	$ 379
Convertible Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 287,500
Interest Rate	0.50%
Conversion rate | $ / shares	$ 19.8088	$ 50.48
Principal amount denomination	$ 1
Threshold percentage of stock price trigger	130%
Threshold trading days | D	20
Threshold consecutive trading days | D	30
Percentage of principal amount redeemed	100%
Cap price | $ / derivative			76.20
Proceeds from notes payable	$ 279,132
Payment of costs of the capped call transactions	34,443
Cost which includes allocated pro-rata on capped call costs	8,428
Long-term Debt		$ 287,500		$ 287,500
Outstanding debt		281,083		280,666
Debt issuance cost		6,417		$ 6,834
Interest expenses		779	$ 553
Amortization of debt discount		417	$ 302
Amount allocated to capped call	$ 60
Number of business day | D	5
Number of consecutive trading day | D	10
Percentage of average conversion value of note	98%
Effective interest rate over period			1.10%
Percentage of premium over last reported sale price			100%
Amount allocated to the Notes	$ 8,368
Revolving Credit Facility, 2019
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 50,000	$ 80,000
Long-term Debt		78,575
Outstanding debt		0
Debt issuance cost		543
Interest expenses		$ 52	$ 121
Revolving Credit Facility, 2019 | London Interbank Offered Rate
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		3.50%
Revolving Credit Facility, 2019 | Base Rate
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.50%

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 19,389	$ 7,675
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	1,128	328
Product and technology
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	7,490	1,822
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	3,989	1,373
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 6,782	$ 4,152

Stock-based Compensation - St_2

Stock-based Compensation - Stock Options (Narrative) (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	Jun. 09, 2021	Jul. 31, 2020	May 31, 2022	May 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense			$ 19,389	$ 7,675
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized to be issued			9,211,901
Common stock available for future grants			5,778,556
Exercise of stock options (shares)			45,755
2020 Equity Incentive Plan | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of option		10 years
Vesting period		4 years
Compensation expense			$ 2,692	2,114
Aggregate intrinsic value of stock options			349	$ 8,774
Unrecognized compensation expense			$ 22,162
Weighted average period			2 years 1 month 6 days
2020 Equity Incentive Plan | Stock Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized to be issued		4,300,000
2020 Equity Incentive Plan | Stock Option | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Vesting percentage		25%
2020 Equity Incentive Plan | Stock Option | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Vesting percentage		75%
PlushCare, Inc. Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of stock options (shares)			24,678
PlushCare, Inc. Stock Incentive Plan | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense			$ 1,244
Exercise of stock options (shares)	48,556
Vested options			6,309
Aggregate intrinsic value of stock options			$ 260,688
Unrecognized compensation expense			$ 6,086
Weighted average period			1 year 8 months 12 days

Stock-based Compensation - St_3

Stock-based Compensation - Stock Option Activity Under Option Plan and Incentive Plan (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Jun. 09, 2021	May 31, 2022
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance		8,045,792
Granted		87,008
Exercised		(45,755)
Forfeited		(91,644)
Ending Balance		7,995,401
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning Balance (in USD per share)		$ 11.24
Granted		7.28
Exercised		14.05
Forfeited		19.84
Ending Balance (in USD per share)		$ 11.20
Weighted remaining contractual life in years		5 years 9 months 18 days
Ending Balance		$ 7,983,093
PlushCare, Inc. Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance		267,721
Exercised		(24,678)
Ending Balance		243,043
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Exercised		$ 1.06
Ending Balance (in USD per share)		$ 1.71
Weighted remaining contractual life in years		7 years 6 months
Ending Balance		$ 1,144,746
PlushCare, Inc. Stock Incentive Plan | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Exercised	(48,556)

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Jun. 09, 2021	Mar. 03, 2021	May 31, 2022	Aug. 31, 2021	May 31, 2021
Summary of activity
Compensation expense			$ 19,389		$ 7,675
Acquisition of 2nd.MD
Summary of activity
Units issued		120,760
PlushCare
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Summary of activity
Units issued	325,992
Time-based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units issued			622,873
Vesting period			4 years
Summary of activity
Beginning Balance			2,226,057
Granted			622,873
Vested			(158,268)
Forfeited			(111,415)
Ending Balance			2,579,247
Compensation expense			$ 6,632		$ 1,630
Remaining of total unrecognized compensation costs			$ 75,958
Weighted average period			3 years 1 month 6 days
Weighted average grant date fair value			$ 14.10
Time-based Restricted Stock Units [Member] | PlushCare
Summary of activity
Compensation expense			$ 183
Number of shares issued in connection with the acquisition to the existing shareholders			64,694
Time-based Restricted Stock Units [Member] | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Vesting percentage			25%
Time-based Restricted Stock Units [Member] | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Vesting percentage			75%
Individuals Agreements With Company [Member] | Acquisition of 2nd.MD
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			2 years
Summary of activity
Ending Balance			241,614
Compensation expense			$ 3,358
Unamortized compensation expense			$ 657
Unamortized Compensation Expense, Weighted Average Remaining Period			8 months 12 days
Shares Eligible To Be Received By Individuals Of Company With Continued Employment			608,332
Additional Shares Eligible To Be Received By Individuals Of Company, Upon Achievement Of Contingent Consideration Milestones			281,531
Grant date fair value price per share			$ 46.56
Shares eligible to receive subject to service requirements			256,418
Separation and transition agreement expenses			$ 3,139
Individuals Agreements With Company [Member] | PlushCare
Summary of activity
Ending Balance			806,161
Compensation expense			$ 3,557
Unamortized compensation expense			$ 28,574
Unamortized Compensation Expense, Weighted Average Remaining Period			2 years 2 months 12 days
Weighted average grant date fair value			$ 52.52
Shares Eligible To Be Received By Individuals Of Company With Continued Employment				806,161
Individuals Agreements With Company [Member] | Tranche One | Acquisition of 2nd.MD
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			50%
Individuals Agreements With Company [Member] | Tranche One | PlushCare
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage				33.33%
Individuals Agreements With Company [Member] | Tranche Two | Acquisition of 2nd.MD
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			50%
Individuals Agreements With Company [Member] | Tranche Two | PlushCare
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage				33.33%
Individuals Agreements With Company [Member] | Tranche Three | PlushCare
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage				33.34%
Restricted Stock Units 2023 Bonus Plan Payout [Member]
Summary of activity
Compensation expense			$ 1,312

Stock-based Compensation - Empl

Stock-based Compensation - Employee Stock Purchase Plan - (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	Mar. 01, 2022	Jul. 31, 2020	May 31, 2022	May 31, 2021	Feb. 28, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense			$ 19,389	$ 7,675
2020 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock initially reserved		1,100,000
Number of automatic annual increase in common share	2,327,976
Percentage of lower in fair market value		85%
Compensation expense			$ 411	$ 391
Issuance of common stock in connection with the employee stock purchase plan (shares)			343,310	50,516
Proceeds from Stock Plans			$ 1,787	$ 1,948
Employee Payroll Contributions Accrued			$ 874		$ 1,511
Maximum | 2020 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of employee contribution on compensation		15%
Participant accrued purchase rights		$ 25,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Income Taxes
Income tax provision (benefit)	$ (3,899)	$ 19
Effective income tax rate	1.10%	0%

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	May 31, 2022	May 31, 2021
Net income (Loss) Per Share Attributable to Common Stockholders
Net income (loss)	$ (342,822)	$ (48,707)
Weighted-average common shares outstanding, basic	69,738,638	58,261,233
Weighted-average common shares outstanding, diluted	69,738,638	58,261,233
Net income (loss) per share attributable to common stockholders, basic	$ (4.92)	$ (0.84)
Net income (loss) per share attributable to common stockholders, diluted	$ (4.92)	$ (0.84)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Antidilutive (Details) - shares	3 Months Ended
	May 31, 2022	May 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	17,679,041	17,148,033
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	8,238,444	8,448,011
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	2,579,247	501,952
Shares issued to 2nd.MD employees and subject to vesting | Acquisition of 2nd.MD
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	274,224	608,332
Shares Issued to PlushCare Employees and Subject to Vesting [Member] | PlushCare
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	831,398
Contingent shares in connection with acquisition | Acquisition of 2nd.MD
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share		1,889,441
Indemnity shares held in escrow in connection with PlushCare acquisition | PlushCare
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	27,342
Shares to be issued to HealthReveal shareholders upon expiration of indemnification period | Health Reveal
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	28,089
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	5,700,297	5,700,297

Commitments and Contingencies -

Commitments and Contingencies - Legal Proceedings (Details) $ in Thousands	May 31, 2022 USD ($)
Commitments and Contingencies.
Accruals related to legal matters	$ 888

Commitments and Contingencies_2

Commitments and Contingencies - Purchase Obligations (Details) $ in Thousands	May 31, 2022 USD ($)
Commitments and Contingencies.
Purchase Obligation	$ 40,323
Purchase obligation, remaining future purchase commitments	$ 36,736